SIRT6 and / or GSPT1 targeting degradation agent and application thereof

By developing degradants targeting SIRT6 and GSPT1, the problem of lack of dual-target degradation drugs in the prior art was solved, and the selective degradation of SIRT6 and GSPT1 proteins in liver cancer cells was achieved, which enhanced the anti-tumor effect and was now in line with the current situation. There are drugs combined to inhibit tumor proliferation.

CN119019370APending Publication Date: 2024-11-26SHENZHEN UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411137552.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-19
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

The lack of degradation drugs targeting the dual targets of SIRT6 and GSPT1 in the prior art, resulting in poor therapeutic effects on liver cancer, and toxic side effects and drug resistance problems.

Method used

Develop a degrading agent targeting SIRT6 and/or GSPT1, using specific compound structures and link arms, prepared by Hoffman alkylation and oxidation reactions, to form compounds with selective degradation capabilities for the treatment of liver cancer.

Benefits of technology

Selective degradation of SIRT6 and GSPT1 proteins was achieved, significantly reducing the level of overexpressed proteins in tumor cells, enhancing the effect of anti-tumor drugs, and in combination with existing drugs to significantly inhibit tumor proliferation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119019370A_ABST
    Figure CN119019370A_ABST
Patent Text Reader

Abstract

The invention discloses a SIRT6 and / or GSPT1 targeting degradation agent and application thereof, and relates to the technical field of compound synthesis. According to the SIRT6 and / or GSPT1 targeting degradation agent provided by the invention, 5-(4-methylpiperizine-1-yl)-2-nitroaniline (5-(4-methylpiperazine)-2-nitroaniline) is taken as an SIRT6 protein ligand, the obtained compound has a SIRT6 and / or GSPT1 targeting degradation effect, SIRT6 and / or GSPT1 protein can be selectively degraded, Western blot experiments prove that the SIRT6 and / or GSPT1 overexpressed protein level in tumor cells can be remarkably reduced, and the SIRT6 and / or GSPT1 targeting degradation agent can be used for preparing a medicine for treating tumor cells. The compound can be used for preparing anti-tumor drugs, and has important significance on new anti-cancer drugs with proprietary intellectual property rights in China for clinical treatment and development of liver cancer tumors in future and guarantee of life health of people in China.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of chemical drug research and development, and in particular to a degradation agent targeting SIRT6 and / or GSPT1 and applications thereof. Background Art

[0002] Liver cancer is known as the king of cancers due to its insidious onset, easy metastasis, and poor prognosis. Liver cancer is the fourth leading cause of cancer-related death worldwide. Surgery, chemotherapy, radiotherapy, and immunotherapy are the four conventional methods of treating liver cancer and other cancers in clinical practice, among which chemotherapy is one of the main methods. However, small molecule chemotherapy drugs for liver cancer in clinical practice often have defects such as large toxic side effects, long-term use causing cancer resistance and off-target risks, and difficulty in obtaining specific targets, resulting in poor treatment effects. Therefore, there is an urgent need to discover and research anti-liver cancer drugs based on new targets and new mechanisms in clinical practice.

[0003] Targeted protein degradation (TPD) is a new drug development technology with great potential in the treatment of tumors, infectious diseases, inflammation and neurodegenerative diseases. Among them, protein degradation targeting chimeras (PROTACs) and molecular glue degraders (MGs) have become highly promising new drug development technologies. They can achieve specific and efficient degradation of disease-related proteins, thereby achieving the effect of disease treatment (Nat. Rev. Cancer. 2021, 21: 638–654; Chem. Soc. Rev. 2022, 51: 5498-5517; J. Med. Chem. 2023, 66: 9278-9296.). Given the unique mechanism of action of PROTACs and molecular glue degraders, they have outstanding advantages in overcoming cancer resistance, reducing side effects and targeting undruggable targets. The use of PROTACs and MGs technology to target and degrade related oncogenic proteins in cancers such as liver cancer is expected to become a new and feasible strategy in clinical cancer treatment.

[0004] Silent information regulator 6 (SIRT6) belongs to type III histone deacetylase, which has dual activity of deacetylase and mono-ADP ribosyltransferase. It participates in many pathological and physiological processes by regulating gene repair and transcription, affecting metabolism, regulating inflammation, etc., and plays an important role in the occurrence, development and chemotherapy resistance of tumors (Subcell Biochem. 2022, 100: 337–360.). SIRT6 is highly expressed in tumors such as liver cancer and is an important target for tumor therapy. Studies have shown that knockout or silencing of SIRT6 gene induces apoptosis of cancer cells such as liver cancer, thereby inhibiting their proliferation. Combining with radiotherapy and chemotherapy can also enhance their sensitivity to radiotherapy or chemotherapy (Oncol. Rep. 2018, 40: 3635–3644.). In addition, G1-S phase transition protein 1 (GSPT1) is a translation termination factor that recognizes the stop codon by binding to eRF1, forcing the protein to separate from the ribosome after translation. GSPT1 is highly expressed in a variety of tumors. Downregulation of GSPT1 can lead to abnormal expression of key proteins in a variety of tumor cells, inhibit proliferation, or induce apoptosis (J. Med. Chem. 2021, 64: 1835-1843.). Recent studies have shown that molecular glue can degrade GSPT1. Currently, molecular glue degraders targeting GSPT1, such as CC-90009, MRT-2359, and BTX-1188, have entered Phase 1 clinical trials and have shown good anti-cancer effects (J. Bioorg. Chem. 2024, 143: 107000–107004.).

[0005] So far, there are few reports on dual degraders that have the advantages of both PROTACs and MGs. Given that silent information regulator 6 (SIRT6) and GSPT1 have important biological functions in the occurrence and development of cancers such as liver cancer, PROTACs and MGs are new protein chemical knockdown technologies. However, there are no reports on dual-target degradation drugs for SIRT6 and GSPT1 at home and abroad. Therefore, the development of new and efficient dual degraders targeting SIRT6 and GSPT1 degradation, combined with radiotherapy and chemotherapy, is of great significance for the future clinical treatment of liver cancer tumors and the development of new anti-cancer drugs with independent intellectual property rights in my country, and for protecting the lives and health of the Chinese people. Summary of the invention

[0006] The technical problem to be solved by the present invention is to provide a degradation agent targeting SIRT6 and / or GSPT1, a preparation method and application thereof.

[0007] In order to solve the above problems, the present invention proposes the following technical solutions:

[0008] In a first aspect, the present invention provides a degradation agent targeting SIRT6 and / or GSPT1, comprising a compound having a structure represented by general formula (1) or a pharmaceutically acceptable salt thereof;

[0009]

[0010] In the formula, X is selected from hydrogen or fluorine;

[0011] M is selected from fluorine, halogen, methyl, methoxy, phenyl, benzyl, nitro, nitrile, 2 / 3-thienyl, 2 / 3-pyridyl, 2 / 3-furyl, N-pyrazolyl, N-piperidine, aniline;

[0012] The value of y is 0 or 1; the value of z is 0 or 1;

[0013] The linker is at least one of an aromatic chain, an aliphatic heterocyclic structure chain, and an aromatic heterocyclic structure chain containing at least one tertiary amine group.

[0014] Further, the compound of the degrader targeting SIRT6 and / or GSPT1 may contain an asymmetric or chiral center and may therefore exist in different stereoisomeric forms. All stereoisomeric forms of the compounds of the present invention include, but are not limited to, diastereomers, enantiomers and atropisomers and mixtures thereof (such as racemates).

[0015] Furthermore, the compound of the degrader targeting SIRT6 and / or GSPT1 may also exist in different tautomeric forms, and "tautomers" or "tautomeric forms" refer to structural isomers of different energies that can be interconverted via a low energy barrier.

[0016] Further, pharmaceutically acceptable salts include addition salts formed with the following acids: hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, benzenesulfonic acid, naphthalene disulfonic acid, acetic acid, propionic acid, lactic acid, trifluoroacetic acid, maleic acid, citric acid, fumaric acid, oxalic acid, tartaric acid, benzoic acid, etc. Hydrochloric acid, hydrobromic acid, sulfuric acid, citric acid, tartaric acid, phosphoric acid, lactic acid, pyruvic acid, acetic acid, trifluoroacetic acid, maleic acid, benzenesulfonic acid, succinic acid and similar known acceptable acid salts.

[0017] Furthermore, the structure of the linker is selected from any one of the structural formulas (a)-(l):

[0018]

[0019] In the structural formulas (a)-(l), the value of m is 0-10, the value of n is 1-8, and the values ​​of m and n are both integers.

[0020] Furthermore, the compound has a structure shown in any of the following:

[0021]

[0022]

[0023]

[0024] Furthermore, the preparation methods of the compounds 6a-6m and 10a-10m are as follows:

[0025] Compound 1 or compound 7 is subjected to a Hofmann alkylation reaction with a linker having an amine group at one end and an alcohol group at the other end to generate an intermediate compound containing an alcohol group;

[0026] Oxidizing the alcohol group of the intermediate compound and reacting with compound 5 to obtain any one of compounds 6a-6m and 10a-10m;

[0027] The structural formula of the compound 1 is as follows:

[0028]

[0029] The structural formula of the compound 7 is as follows:

[0030]

[0031] The structural formula of the compound 5 is as follows:

[0032]

[0033] Furthermore, the preparation methods of the compounds 12a-12g and 13a-13g are as follows:

[0034] Compound 1 or compound 7 is subjected to a Hofmann alkylation reaction with a linker having an amine group at one end and an alcohol group at the other end to generate an intermediate compound containing an alcohol group;

[0035] Oxidizing the alcohol group of the intermediate compound and reacting it with compound 11 to obtain any one of compounds 12a-12g and 13a-13g;

[0036] The structural formula of the compound 1 is as follows:

[0037]

[0038] The structural formula of the compound 7 is as follows:

[0039]

[0040] The structural formula of the compound 11 is as follows:

[0041]

[0042] Further, the compound 11 is obtained by reacting the compound 5 with a compound containing an amine protecting group;

[0043] The structural formula of the compound 5 is as follows:

[0044]

[0045] The structural formula of the compound containing amine protecting group is as follows:

[0046]

[0047] Furthermore, the amine group is a secondary amine group.

[0048] Further, the alcohol group of the intermediate compound is oxidized using a Dess-Martin oxidant.

[0049] In a second aspect, the present invention provides a pharmaceutical composition, comprising the degrader targeting SIRT6 and GSPT1.

[0050] The pharmaceutical composition of the present invention may include the aforementioned SIRT6 and / or GSPT1 targeting degradation agent compound and its pharmaceutically acceptable salt, hydrate as an active ingredient, mixed with a pharmaceutically acceptable excipient to prepare a pharmaceutical composition, and prepared into a clinically acceptable dosage form, wherein the above excipient refers to a diluent, adjuvant or carrier that can be used in the pharmaceutical field. The above dosage form refers to injections, tablets, capsules, etc. commonly used in clinical practice.

[0051] In a third aspect, the present invention provides use of the SIRT6 and / or GSPT1 targeting degrader as described in the first aspect in the preparation of a regulator or anti-tumor drug targeting SIRT6 and / or GSPT1 protein.

[0052] The tumor is a solid tumor or a hematological malignancy, including but not limited to liver cancer, prostate cancer, breast cancer, etc.

[0053] Furthermore, in the anti-tumor drug, the degradation agent targeting SIRT6 and / or GSPT1 can be used alone as the only anti-tumor drug, or can be used in combination with other tumor therapeutic drugs for the treatment or prevention of tumors.

[0054] Compared with the prior art, the technical effects achieved by the present invention include:

[0055] The SIRT6 and / or GSPT1 targeting degradation agent provided by the present invention uses 5-(4-methylpiperazin-1-yl)-2-nitroaniline (5-(4-methylpiperazine)-2-nitroaniline) as a SIRT6 protein ligand and a CRBN derivative as an E3 ligase ligand. The obtained compound has the effect of targeting SIRT6 and / or GSPT1 degradation and can selectively degrade SIRT6 and / or GSPT1 proteins. Protein immunoblotting experiments (Western Blot) confirm that it can significantly reduce the level of overexpressed SIRT6 and / or GSPT1 proteins in tumor cells. It can be used to prepare anti-tumor drugs, which is of great significance for the future clinical treatment of liver cancer tumors and the development of new anti-cancer drugs with my country's independent intellectual property rights, and for protecting the life and health of the Chinese people. BRIEF DESCRIPTION OF THE DRAWINGS

[0056] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the accompanying drawings required for use in the description of the embodiments will be briefly introduced below. Obviously, the accompanying drawings described below are some embodiments of the present invention. For ordinary technicians in this field, other accompanying drawings can be obtained based on these accompanying drawings without paying any creative work.

[0057] Figure 1 The Western Blot results of the degradation of SIRT6 protein by each compound in SK-HEP-1.

[0058] Figure 2 The WB results of different concentrations of compounds 6b and 6c degrading SIRT6 protein in SK-HEP-1 cells; and the WB results of different concentrations of compounds 10c and 10f degrading GSPT1 protein in SK-HEP-1 cells

[0059] Figure 3 The WB results of different concentrations of compounds 6e, 6f, 10e, 10j and 10m degrading SIRT6 protein in Huh-7 cells.

[0060] Figure 4 These are the experimental results of animal models. DETAILED DESCRIPTION

[0061] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments. Obviously, the embodiments described below are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0062] Example 1

[0063] Compound 6a was prepared by the following synthetic route:

[0064]

[0065] The specific steps are:

[0066] (1) Compound 1 (110 mg, 0.40 mmol) and compound 2a (39 mg, 0.45 mmol) were weighed and dissolved in anhydrous DMF (5 mL), and DIPEA (0.23 mL, 1.35 mmol) was added. The reaction solution was heated to 100°C and stirred for 4 h. The reaction was monitored by TLC. After the reaction was completed, the mixture was cooled to room temperature, saturated saline and dichloromethane were added, and the organic phases were combined. The residue 3a was distilled under reduced pressure and used in the next step without purification. 3a was dissolved in dichloromethane (10 mL), Dess-Martin oxidant (0.25 g, 0.60 mmol) was slowly added, and the reaction was continued at room temperature for 1 h. After the reaction was completed, saturated sodium sulfite solution was added, stirred for 10 min, the organic phase was separated, concentrated, and purified by column chromatography (DCM / MeOH=50:1 to 25:1) to obtain yellow compound 4a.

[0067] (2) Compound 4a (36 mg, 0.10 mmol) and compound 5 (22 mg, 0.10 mmol) were weighed and dissolved in a mixed solvent of DCM / MeOH (5:1, v / v), cooled to 5°C, and a few drops of HOAc were added. After the reaction solution was stirred for 10 minutes, Na(AcO)3BH (64 mg, 0.3 mmol) was added. The temperature was slowly returned to room temperature and the reaction was continued to stir for 12 hours. Saturated NaHCO3 solution was added to the reaction, stirred for 5 minutes, extracted with dichloromethane, the organic phases were combined, concentrated, and purified by column (DCM / MeOH = 50:1 to 25:1) to obtain yellow compound 6a.

[0068] 1-(2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)azetidine-3-carbaldehyde(4a). Yellowish solid (115 mg, 84%). 1HNMR(600MHz,DMSO-d6):δ11.09(s,1H),9.86(s,1H),8.02(d,J=8.0Hz,1H),7.96-7.98(m,1H),7.82(d,J=8.0Hz,1H),5.05-5.10(m,1H),4.17-4.22(m,2H),4.01-4.05(m,1H),3.82-3.86(m,1H),3.70-3.72(m,1H),2.86-2.92(m,2H),2.52-2.62(m,2H),2.00-2.04(m,1H).HRMS(EI):calcd For[C 17 H 16 N3O5](M+H) + ,342.1084;found,342.1092.

[0069] 5-(3-((4-(3-Amino-4-nitrophenyl)piperazin-1-yl)methyl)azetidin-1-yl)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione(6a).Yellowish solid(37mg,68%). 1 HNMR(600MHz,DMSO-d6):δ11.08(s,1H),7.81(d,J=8.0Hz,1H),7.64(d,J=8.0Hz,1H),7.27(s,2H),6.65-6.66(m,1H),6.40-6.42(m,1H),6.21-6.22(m,1H),5.04-5.07(m,1H),4.14-4.17(m,2H),3.70-3.73(m,2H),3.03-3.06(m,1H),2.85-2.91(m,1H),2.65-.2.66(m,2H),2.53-2.60(m,10H),2.00-2.03(m,1H). 13 C NMR(150MHz,DMSO-d6):δ173.2,170.6,167.9,167.6,155.6,155.4,148.8,134.3,127.6,125.3,123.4,117.1,114.5,105.8,104.8,97.9,62.0,56.1,52.8,49.2,46.6,31.4,27.4,22.6.HRMS(EI):calcd For[C 27 H 30 N7O6](M+H)+ ,548.2252;found,548.2250.

[0070] Example 2

[0071] Compound 6b was prepared, and its structural formula is as follows:

[0072]

[0073] Referring to the method in Example 1, compound 1 was reacted with pyrrolidin-3-ylmethanol to synthesize intermediate 4b after oxidation; intermediate 4b was then reacted with compound 5 to obtain compound 6b, a total of 39 mg, with a yield of 70%, and a yellow solid powder.

[0074] 1-(2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)pyrrolidine-3-carbaldehyde(4b). Yellowish solid (112 mg, 79%). 1 HNMR (600MHz, DMSO-d6): δ11.03(s,1H),9.75(s,1H),8.13(d,J=8.0Hz,1H),7.80(t,J=8.0Hz,1H),7.69-7.72(m,1H),4.97-5.00(m,1H),3.57- 3.69(m,1H),3.48-3.52(m,2H),2.81-2.86(m,1H),2.65-2.71(m,3H),2.40-2.42(m,2H),2.33-2.36(m,1H),2.05-2.08(m,1H).HRMS(EI):calcd For[C 18 H 18 N3O5](M+H) + ,356.1241;found,356.1239.

[0075] 5-(3-((4-(3-Amino-4-nitrophenyl)piperazin-1-yl)methyl)pyrrolidin-1-yl)-2-(2,6-dioxopiperidi n-3-yl)isoindoline-1,3-dione(6b). Yellowish solid (39 mg, 70%). 1HNMR (600MHz, DMSO-d6): δ11.08(s,1H),7.81(d,J=8.0Hz,1H),7.65(d,J=8.0Hz,1H),7.27(s ,2H),6.91(s,1H),6.82-6.84(m,1H),6.40-6.42(m,1H),6.22(s,1H),5.05-5.08(m,1H),3.5 4-3.61(m,1H),3.50-3.53(m,2H),3.38-3.44(m,3H),3.15-3.17(m,1H),2.86-2.92(m,1H),2 .51-2.69(m,7H),2.39-2.42(m,2H),2.14-2.17(m,1H),2.00-2.03(m,1H),1.76-1.80(m,1H). 13 C NMR (150MHz, DMSO-d6): δ173.2,170.6,168.2,167.7,155.4,152.3,148.8,134.5,127.6,125.4,123.3,115 .9,115.7,105.9,105.8,97.8,61.2,53.1,52.6,49.1,47.6,46.7,35.9,31.5,29.6,22.7.HRMS(EI):calcd For[C 28 H 32 N7O6](M+H) + ,562.2409;found,562.2414.

[0076] Example 3

[0077] Compound 6c was prepared, and its structural formula is as follows:

[0078]

[0079] Referring to the method in Example 1, compound 1 was reacted with piperidin-4-ylmethanol to synthesize intermediate 4c after oxidation; intermediate 4c was then reacted with compound 5 to obtain compound 6c, a total of 43 mg, a yield of 75%, and a yellow solid powder.

[0080] 1-(2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidine-4-carbaldehyde(4c). Yellowish solid (118 mg, 80%). 1HNMR(600MHz,DMSO-d6):δ11.08(s,1H),9.63(s,1H),7.66(d,J=8.0Hz,1H),7.35(s,1H),7.26(d,J=8.0Hz,1H),5.06-5.09(m,1H),3.93-3.96(m,2H),3.11-3.20(m,2H),2.87-2.91(m,3H),2.57-2.61(m,2H),2.01-2.03(m,1H),1.92-1.95(m,2H),1.55-1.58(m,2H).HRMS(EI):calcd For[C 19 H 20 N3O5](M+H) + ,370.1397;found,370.1400.

[0081] 5-(4-((4-(3-Amino-4-nitrophenyl)piperazin-1-yl)methyl)piperidin-1-yl)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione(6c).Yellowish solid(43mg,75%). 1 HNMR(600MHz,DMSO-d6):δ11.09(s,1H),7.81(d,J=8.0Hz,1H),7.66(d,J=8.0Hz,1H),7.25-7.32(m,3H),7.23-7.24(m,1H),6.39-6.41(m,1H),6.21(s,1H),5.05-5.08(m,1H),4.04-4.07(m,2H),3.32-3.35(m,3H),2.96(t,J=6.0Hz,2H),2.86-2.90(m,1H),2.58-2.61(m,3H),2.45-2.50(m,4H),2.19(d,J=6.0Hz,2H),2.00-2.04(m,1H),1.81-1.88(m,3H),1.14-1.20(m,2H). 13C NMR (150MHz, DMSO-d6): δ173.2,170.6,168.1,167.4,155.4,148.8,134.5,127.6,125.5,123.3,118 .0,117.8,108.1,105.8,97.8,64.0,53.2,49.1,47.7,46.7,32.8,31.5,30.0,22.7.HRMS(EI):calcd For[C 29 H 34 N7O6](M+H) + ,576.2565;found,576.2568.

[0082] Example 4

[0083] Compound 6d was prepared, and its structural formula is as follows:

[0084]

[0085] Referring to the method in Example 1, compound 1 was reacted with piperidin-3-ylmethanol to synthesize intermediate 4d after oxidation; intermediate 4d was then reacted with compound 5 to obtain compound 6d, a total of 35 mg, with a yield of 60%, and a yellow solid powder.

[0086] 1-(2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidine-3-carbaldehyde(4d). Yellowish solid (111 mg, 75%). 1 HNMR (600MHz, DMSO-d6): δ11.09(s,1H),9.68(s,1H),7.67-7.69(m,1H),7.39(s,1H),7 .28-7.30(m,1H),5.07-5.10(m,1H),3.91-3.94(m,1H),3.65-3.67(m,1H),3.48-3.51(m ,1H),3.24-3.27(m,1H),2.86-2.92(m,1H),2.61-2.67(m,1H),2.52-2.59(m,2H),2.01 -2.04(m,1H),1.91-1.95(m,1H),1.65-1.75(m,2H),1.57-1.60(m,1H).HRMS(EI):calcd For[C 19 H 20 N3O5](M+H) +,370.1397;found,370.1401.

[0087] 5-(3-((4-(3-Amino-4-nitrophenyl)piperazin-1-yl)methyl)piperidin-1-yl)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione(6d). Yellowish solid (35 mg, 60%). 1 HNMR (600MHz, DMSO-d6): δ11.08(s,1H),7.82(d,J=8.0Hz,1H),7.66(d,J=8.0Hz,1H),7.27-7.30(m,3H),7.21 -7.23(m,1H),6.39-6.42(m,1H),6.23(s,1H),5.05-5.08(m,1H),3.83-3.90(m,2H),3.36-3.41(m,3H),3.15-3 .19(m,1H),2.97-3.01(m,1H),2.86-2.92(m,1H),2.52-2.61(m,5H),2.39-2.42(m,2H),2.31-2.33(m,1H),2.1 4-2.17(m,1H),1.99-2.04(m,1H),1.82-1.90(m,2H),1.69-1.73(m,1H),1.52-1.56(m,1H),1.24-1.31(m,1H). 13 C NMR (150MHz, DMSO-d6): δ173.2,170.6,168.1,167.4,155.4,148.8,134.6,127.6,125.6,123.4,117.7,11 7.4,107.8,105.8,97.8,60.9,53.2,52.0,49.1,48.6,46.7,32.5,31.4,28.9,23.8,22.6.HRMS(EI):calcd For[C 29 H 34 N7O6](M+H) + ,576.2565;found,576.2573.

[0088] Example 5

[0089] Compound 6e was prepared, and its structural formula is as follows:

[0090]

[0091] Referring to the method in Example 1, compound 1 was reacted with 2-(piperidin-4-yl)ethan-1-ol to synthesize intermediate 4e after oxidation; intermediate 4e was then reacted with compound 5 to obtain compound 6e, a total of 40 mg, with a yield of 68%, and a yellow solid powder.

[0092] 2-(1-(2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidin-4-yl)acetaldehyde(4e). Yellowish solid (116 mg, 76%). 1 HNMR (600MHz, DMSO-d6): δ11.08(s,1H),9.70(s,1H),7.65(d,J=8.0Hz,1H),7.3 1-7.32(m,1H),7.23-7.24(m,1H),5.05-5.08(m,1H),4.02-4.05(m,2H),2.98-3. 02(m,2H),2.86-2.91(m,2H),2.52-2.61(m,2H),2.41-2.42(m,1H),2.11-2.14( m,1H),2.00-2.04(m,1H),1.73-1.75(m,2H),1.21-1.28(m,2H).HRMS(EI):calcd For[C 20 H 22 N3O5](M+H) + ,384.1554;found,384.1560.

[0093] 5-(4-(2-(4-(3-Amino-4-nitrophenyl)piperazin-1-yl)ethyl)piperidin-1-yl)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione(6e). Yellowish solid (40mg, 68%). 1HNMR (600MHz, DMSO-d6): δ11.09(s,1H),7.81(d,J=8.0Hz,1H),7.65(d,J=8.0Hz,1H),7.22-7 .30(m,4H),6.38-6.40(m,1H),6.20-6.21(m,1H),5.06-5.08(m,1H),4.03-4.06(m,1H),3.30 -3.52(m,4H),2.86-2.98(m,3H),2.54-2.61(m,3H),2.45-2.49(m,4H),2.35-2.37(m,2H),2. 00-2.03(m,1H),1.76-1.79(m,2H),1.60-1.62(m,1H),1.40-1.44(m,2H),1.18-1.23(m,1H). 13 C NMR (150MHz, DMSO-d6): δ173.3,170.6,168.1,167.4,155.4,155.3,148.8,134.5,127.6,125.4,123.4,118 .0,117.7,108.2,105.8,97.8,55.6,52.9,49.2,47.9,46.7,33.9,33.2,31.6,31.5,22.6.HRMS(EI):calcd For[C 30 H 36 N7O6](M+H) + ,590.2722;found,590.2789.

[0094] Example 6

[0095] Compound 6f was prepared, and its structural formula is as follows:

[0096]

[0097] Referring to the method in Example 1, compound 1 was reacted with 3-(piperidin-4-yl)propan-1-ol to synthesize intermediate 4f; intermediate 4f was then reacted with compound 5 to obtain compound 6f, a total of 35 mg, with a yield of 58%, as a yellow solid powder.

[0098] 3-(1-(2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidin-4-yl)propanal(4f).Yellowish solid(125mg,79%). 1HNMR(600MHz,DMSO-d6):δ11.08(s,1H),9.69(s,1H),7.64-7.66(m,1H),7.31(s,1H),7.23-7.24(m,1H),5.05-5.08(m,1H),4.03-4.07(m,2H),2.87-2.95(m,3H),2.54-2.61(m,2H),2.48-2.52(m,3H),2.00-2.03(m,1H),1.73-1.75(m,2H),1.47-1.53(m,2H),1.14-1.19(m,2H).HRMS(EI):calcd For[C 21 H 24 N3O5](M+H) + ,398.1710;found,398.1720.

[0099] 5-(4-(3-(4-(3-Amino-4-nitrophenyl)piperazin-1-yl)propyl)piperidin-1-yl)-2-(2,6-dioxopiperidi n-3-yl)isoindoline-1,3-dione(6f).Yellowish solid(35mg,58%). 1 HNMR(600MHz,DMSO-d6):δ11.09(s,1H),7.81(d,J=8.0Hz,1H),7.65(d,J=8.0Hz,1H),7.23-7.31(m,3H),7.22-7.23(m,1H),6.38-6.40(m,1H),6.21(s,1H),5.05-5.09(m,1H),4.04-4.06(m,2H),3.30-3.32(m,4H),2.86-2.96(m,3H),2.53-2.61(m,2H),2.45-2.46(m,4H),2.30(t,J=6.0Hz,2H),2.01-2.03(m,1H),1.75-1.77(m,2H),1.47-1.56(m,3H),1.19-1.26(m,2H),1.13-1.17(m,2H). 13C NMR (150MHz, DMSO-d6): δ173.2,170.6,168.1,165.4,155.4,155.3,148.8,134.5,127.6,125.4,123.4,118.0 ,117.7,108.1,105.8,97.8,58.4,52.8,49.1,47.9,46.7,35.6,34.2,31.6,31.4,23.8,22.6.HRMS(EI):calcd For[C 31 H 38 N7O6](M+H) + ,604.2878;found,604.2968.

[0100] Example 7

[0101] Compound 6g was prepared, and its structural formula is as follows:

[0102]

[0103] Referring to the method in Example 1, compound 1 was reacted with (3-azabicyclo[3.1.0]hexan-6-yl)methanol to synthesize intermediate 4g; intermediate 4g was then reacted with compound 5 to obtain compound 6g, a total of 45 mg, with a yield of 79%, and a yellow solid powder.

[0104] 3-(2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)-3-azabicyclo[3.1.0]

[0105] hexane-6-carbaldehyde(4g).Yellowish solid(132mg,90%). 1 HNMR (600MHz, DMSO-d6): δ11.08(s,1H),9.17(d,J=6.0Hz,1H),7.66(d,J=8.0Hz,1H),6.95(s,1H),6.84-6.86(m,1H),5.05-5.08(m,1H),3.78- 3.80(m,2H),3.56-3.58(m,2H),2.86-2.92(m,1H),2.57-2.61(m,1H),2.54-2.55(m,3H),2.01-2.04(m,1H),1.79-1.81(m,1H).HRMS(EI):calcd For[C 19 H 18 N3O5](M+H)+ ,368.1241;found,368.1238.

[0106] 5-(6-((4-(3-Amino-4-nitrophenyl)piperazin-1-yl)methyl)-3-azabicyclo[3.1.0]hexan-3-yl)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (6g). Yellowish solid (45mg, 79%). 1 HNMR (600MHz, DMSO-d6): δ11.08(s,1H),7.81(d,J=8.0Hz,1H),7.63(d,J=8.0Hz,1H),7.2 8(s,1H),6.91-6.92(m,1H),6.81-6.83(m,1H),6.39-6.41(m,1H),6.22(s,1H),5.04-5.07 (m,1H),3.68-3.69(m,2H),3.44-3.46(m,3H),2.86-2.92(m,1H),2.50-2.61(m,8H),2.34 -2.35(m,2H),2.00-2.03(m,1H),1.66-1.68(m,2H),0.82-0.86(m,1H),0.74-0.77(m,1H). 13 C NMR (150MHz, DMSO-d6): δ173.2,170.6,168.1,167.7,155.4,152.8,148.8,134.3,127.6,125.3,123.3, 116.7,116.3,106.5,105.8,97.8,59.9,55.4,52.5,50.9,49.2,46.6,31.5,22.7,22.6.HRMS(EI):calcd For[C 29 H 32 N7O6](M+H) + ,574.2409;found,574.2426.

[0107] Example 8

[0108] Compound 6h was prepared, and its structural formula is as follows:

[0109]

[0110] Referring to the method in Example 1, compound 1 was reacted with (4-fluoropiperidin-4-yl)methanol to synthesize intermediate 4h; intermediate 4h was then reacted with compound 5 to obtain compound 6h, a total of 32 mg, with a yield of 54%, and a yellow solid powder.

[0111] 1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)-4-fluoropiperidine-4-carbaldehyde(4h).Yellowish solid(125mg, 81%). 1 HNMR (600MHz, DMSO-d6): δ11.07(s,1H),9.63(s,1H),7.68(d,J=8.0Hz,1H),7.35(s,1H),7.26(d,J=8.0Hz,1H),5.06-5.10(m,1H),3.90-3.9 4(m,2H),3.11-3.20(m,2H),2.88-2.90(m,2H),2.58-2.61(m,2H),2.01-2.04(m,1H),1.91-1.96(m,2H),1.56-1.59(m,2H).HRMS(EI):calcd For[C 19 H 19 FN3O5](M+H) + ,388.1303;found,368.1240.

[0112] 5-(4-((4-(3-amino-4-nitrophenyl)piperazin-1-yl)methyl)-4-fluoropiperidin-1-yl)-2-(2,6-dioxo piperidin-3-yl)isoindoline-1,3-dione(6h).Yellowish solid(32mg, 54%). 1HNMR (600MHz, DMSO-d6): δ11.09(s,1H),7.82(d,J=8.0Hz,1H),7.64(d,J=8.0Hz,1H),7.24-7 .32(m,3H),7.22-7.23(m,1H),6.39-6.41(m,1H),6.23(s,1H),5.06-5.08(m,1H),4.06-4.08 (m,2H),3.31-3.35(m,3H),2.96(t,J=6.0Hz,2H),2.86-2.90(m,1H),2.58-2.62(m,2H),2.45 -2.50(m,4H),2.20(d,J=6.0Hz,2H),2.01-2.04(m,1H),1.83-1.87(m,3H),1.14-1.20(m,2H). 13 C NMR (150MHz, DMSO-d6): δ173.3,170.6,168.0,167.5,155.4,148.8,134.6,127.6,125.5,124.3,118.1, 117.9,108.1,105.8,98.8,64.0,54.2,49.1,47.8,46.7,32.9,31.5,30.6,22.8.HRMS(EI):calcdFor[C 29 H 33 FN7O6](M+H) + ,594.2471;found,574.2426.

[0113] Example 9

[0114] Compound 6i was prepared, and its structural formula is as follows:

[0115]

[0116] Referring to the method in Example 1, compound 1 was reacted with [1,4'-bipiperidin]-4-ylmethanol to synthesize intermediate 4i; intermediate 4i was then reacted with compound 5 to obtain compound 6i, a total of 37 mg, with a yield of 56%, and a yellow solid powder.

[0117] 1'-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)-[1,4'-bipiperidine]-4-carbaldehyde(4i). Yellowish solid (121 mg, 67%). 1HNMR(600MHz,DMSO-d6):δ11.09(s,1H),9.64(s,1H),7.68(d,J=8.0Hz,1H),7.36(s,1H),7.28(d,J=8.0Hz,1H),5.06-5.10(m,1H),3.90-3.98(m,4H),3.12-3.21(m,4H),2.88-2.91(m,3H),2.56-2.60(m,2H),2.00-2.03(m,1H),1.78-1.97(m,6H),1.55-1.59(m,3H).HRMS(EI):calcd For[C 24 H 29 N4O5](M+H) + ,453.2132;found,453.2138.

[0118] 5-(4-((4-(3-amino-4-nitrophenyl)piperazin-1-yl)methyl)-[1,4'-bipiperidin]-1'-yl)-2-(2,6-dioxo piperidin-3-yl)isoindoline-1,3-dione(6i).Yellowish solid(37mg,56%). 1 HNMR(600MHz,DMSO-d6):δ11.09(s,1H),7.82(d,J=8.0Hz,1H),7.68(d,J=8.0Hz,1H),7.26-7.30(m,3H),7.23-7.26(m,1H),6.35-6.40(m,1H),6.21(s,1H),5.05-5.10(m,1H),4.03-4.08(m,2H),3.30-3.68(m,7H),2.96(t,J=6.0Hz,2H),2.86-2.90(m,1H),2.57-2.61(m,3H),2.46-2.50(m,4H),2.20(d,J=6.0Hz,2H),2.01-2.05(m,2H),1.83-1.90(m,7H),1.16-1.25(m,2H). 13C NMR (150MHz, DMSO-d6): δ173.3,170.4,168.2,167.6,155.4,148.9,134.6,127.6,125.8,123.3,118.2,117.8 ,108.3,105.9,98.1,64.1,53.3,49.1,47.8,46.7,46.5,34.7,32.8,31.5,30.0,28.2,22.7.HRMS(EI):calcd For[C 34 H 43 N8O6](M+H) + ,659.3300;found,659.3310.

[0119] Example 10

[0120] Compound 6j was prepared, and its structural formula is as follows:

[0121]

[0122] Referring to the method in Example 1, compound 1 was reacted with (1-(azetidin-3-yl)piperidin-4-yl)methanol to synthesize intermediate 4j; intermediate 4j was then reacted with compound 5 to obtain compound 6j, a total of 30 mg, with a yield of 51%, and a yellow solid powder.

[0123] 1-(1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)azetidin-3-yl)piperidine-4-carbald ehyde(4j).Yellowish solid(110mg, 65%). 1 HNMR (600MHz, DMSO-d6): δ11.09(s,1H),9.87(s,1H),8.02(d,J=8.0Hz,1H),7.97 -7.98(m,1H),7.83(d,J=8.0Hz,1H),5.04-5.10(m,1H),4.18-4.22(m,2H),4.02- 4.05(m,1H),3.83-3.87(m,1H),3.70-3.72(m,1H),3.10-3.15(m,4H),2.87-2.93 (m,2H),2.54-2.60(m,3H),2.00-2.04(m,1H),1.42-144(m,2H).HRMS(EI):calcd For[C 22 H 25N4O5](M+H) + ,425.1819;found,425.1825.

[0124] 5-(3-(4-((4-(3-amino-4-nitrophenyl)piperazin-1-yl)methyl)piperidin-1-yl)azetidin-1-yl)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione(6j). Yellowish solid (30 mg, 51%). 1 HNMR (600MHz, DMSO-d6): δ11.08(s,1H),7.82(d,J=8.0Hz,1H),7.64(d,J=8.0Hz,1H),7 .28(s,2H),6.64-6.70(m,1H),6.40-6.42(m,1H),6.20-6.22(m,1H),5.04-5.08(m,1H) ,4.13-4.18(m,2H),3.70-3.74(m,2H),3.12-3.14(m,4H),3.04-3.06(m,1H),2.86-2.9 1(m,1H),2.63-.2.66(m,3H),2.54-2.60(m,10H),2.01-2.04(m,1H),1.44-1.46(m,2H). 13 C NMR (150MHz, DMSO-d6): δ173.2,170.8,167.9,167.7,155.8,155.4,148.9,134.4,127.6,125.4,123.4,117.2 ,114.6,105.8,104.8,98.0,62.0,56.2,52.8,49.4,46.6,46.4,34.6,31.4,28.2,27.4,22.8.HRMS(EI):calcd For[C 29 H 33 FN7O6](M+H) + ,594.2471;found,594.2489.

[0125] Embodiment 11

[0126] Compound 6k was prepared, and its structural formula is as follows:

[0127]

[0128] Referring to the method in Example 1, compound 1 was reacted with (1-(piperidin-4-ylmethyl)piperidin-4-yl)methanol to synthesize intermediate 4k; intermediate 4k was then reacted with compound 5 to obtain compound 6k, a total of 32 mg, with a yield of 48%, and a yellow solid powder.

[0129] 1-((1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidin-4-yl)methyl)piperidine-4-carbaldehyde(4k). Yellowish solid (114 mg, 61%). 1 HNMR (600MHz, DMSO-d6): δ11.09(s,1H),9.65(s,1H),7.70(d,J=8.0Hz,1H),7.38(s,1H),7.28(d,J=8.0Hz,1H),5.06-5.10(m,1H),3.91-3.9 8(m,4H),3.13-3.22(m,4H),2.88-2.91(m,3H),2.58-2.60(m,2H),2.00-2.10(m,3H),1.78-1.98(m,6H),1.56-1.60(m,3H).HRMS(EI):calcd For[C 25 H 31 N4O5](M+H) + ,467.2289;found,467.2295.

[0130] 5-(4-((4-((4-(3-amino-4-nitrophenyl)piperazin-1-yl)methyl)piperidin-1-yl)methyl)

[0131] piperidin-1-yl)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione(6k).Yellowish solid(32mg, 48%). 1HNMR (600MHz, DMSO-d6): δ11.09(s,1H),7.84(d,J=8.0Hz,1H),7.68(d,J=8.0Hz,1H),7.24-7 .28(m,3H),7.23-7.26(m,1H),6.35-6.40(m,1H),6.21(s,1H),5.06-5.10(m,1H),4.04-4.07 (m,2H),3.30-3.68(m,7H),2.98(t,J=6.0Hz,2H),2.87-2.90(m,1H),2.58-2.60(m,3H),2.46 -2.50(m,4H),2.21(d,J=6.0Hz,2H),2.02-2.10(m,4H),1.83-1.90(m,7H),1.17-1.26(m,2H). 13 C NMR (150MHz, DMSO-d6): δ173.4,170.4,168.5,167.6,155.6,149.0,134.6,127.8,125.8,123.4,118.3,117.8,1 08.3,106.0,98.4,64.1,61.8,53.6,49.2,47.8,46.8,46.6,34.8,32.8,31.6,30.2,28.4,22.8.HRMS(EI):calcd For[C 35 H 45 N8O6](M+H) + ,673.3457;found,673.3460.

[0132] Example 12

[0133] Compound 61 was prepared, and its structural formula is as follows:

[0134]

[0135] Referring to the method in Example 1, compound 1 was reacted with (1-(piperidin-4-ylmethyl)azetidin-3-yl)methanol to synthesize intermediate 4l; intermediate 4l was then reacted with compound 5 to obtain compound 6l, a total of 25 mg, a yield of 39%, and a yellow solid powder.

[0136] 1-((1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperidin-4-yl)methyl)azetidine-3-carbaldehyde(4l).Yellowish solid(103mg,59%). 1 HNMR(600MHz,DMSO-d6):δ11.10(s,1H),9.87(s,1H),8.04(d,J=8.0Hz,1H),7.97-7.98(m,1H),7.86(d,J=8.0Hz,1H),5.04-5.10(m,1H),4.18-4.22(m,2H),4.01-4.06(m,1H),3.83-3.88(m,1H),3.70-3.72(m,1H),3.11-3.17(m,4H),2.88-2.94(m,2H),2.54-2.60(m,3H),2.00-2.11(m,3H),1.41-143(m,2H).HRMS(EI):calcd For[C 23 H 27 N4O5](M+H) + ,439.1976;found,439.1986.

[0137] 5-(4-((3-((4-(3-amino-4-nitrophenyl)piperazin-1-yl)methyl)azetidin-1-yl)methyl)

[0138] piperidin-1-yl)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione(6l).Yellowish solid(25mg,39%). 1HNMR (600MHz, DMSO-d6): δ11.08(s,1H),7.83(d,J=8.0Hz,1H),7.64(d,J=8.0Hz,1H),7 .27(s,2H),6.64-6.70(m,1H),6.41-6.43(m,1H),6.20-6.22(m,1H),5.05-5.09(m,1H) ,4.13-4.18(m,2H),3.72-3.75(m,2H),3.12-3.14(m,4H),3.05-3.06(m,1H),2.86-2.9 2(m,1H),2.62-.2.64(m,3H),2.53-2.59(m,10H),2.01-2.12(m,3H),1.44-1.46(m,2H). 13 C NMR (150MHz, DMSO-d6): δ173.4,170.8,168.0,167.7,155.9,155.4,148.9,134.8,127.6,125.7,123.4,117.9,11 4.6,105.8,105.1,98.0,62.8,61.9,56.4,52.8,49.4,46.8,46.4,34.8,31.6,28.2,27.6,22.8.HRMS(EI):calcd For[C 33 H 41 N8O6](M+H) + ,645.3144;found,645.3153.

[0139] Embodiment 13

[0140] Compound 6m was prepared, and its structural formula is as follows:

[0141]

[0142] Referring to the method in Example 1, compound 1 was reacted with (1-((4-fluoropiperidin-4-yl)methyl)piperidin-4-yl)methanol to synthesize intermediate 4m; intermediate 4m was then reacted with compound 5 to obtain compound 6m, a total of 30 mg, with a yield of 44%, as a yellow solid powder.

[0143] 1-((1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)-4-fluoropiperidin-4-yl)methyl)pi peridine-4-carbaldehyde(4l).Yellowish solid(73mg,38%). 1 HNMR(600MHz,DMSO-d6):δ11.09(s,1H),9.65(s,1H),7.72(d,J=8.0Hz,1H),7.40(s,1H),7.28(d,J=8.0Hz,1H),5.04-5.09(m,1H),3.91-3.98(m,4H),3.14-3.23(m,4H),2.88-2.91(m,3H),2.57-2.60(m,2H),2.00-2.10(m,3H),1.77-1.99(m,6H),1.56-1.60(m,2H).HRMS(EI):calcd For[C 25 H 30 FN4O5](M+H) + ,485.2195;found,485.2200.

[0144] 5-(4-((4-((4-(3-amino-4-nitrophenyl)piperazin-1-yl)methyl)piperidin-1-yl)methyl)-4-fluoropi peridin-1-yl)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione(6m).Yellowish solid(30mg,44%). 1HNMR (600MHz, DMSO-d6): δ11.09(s,1H),7.85(d,J=8.0Hz,1H),7.68(d,J=8.0Hz,1H),7.25-7 .29(m,3H),7.23-7.26(m,1H),6.36-6.41(m,1H),6.23(s,1H),5.06-5.10(m,1H),4.06-4.08 (m,2H),3.30-3.68(m,7H),2.98(t,J=6.0Hz,2H),2.88-2.91(m,1H),2.58-2.60(m,3H),2.47 -2.51(m,4H),2.21(d,J=6.0Hz,2H),2.01-2.09(m,4H),1.82-1.89(m,7H),1.18-1.26(m,1H). 13 C NMR (150MHz, DMSO-d6): δ173.3,170.4,168.6,167.6,155.8,149.0,134.3,127.8,125.4,123.4,118.6,117.8,1 08.4,106.0,98.7,64.1,61.8,53.6,49.3,47.8,46.9,46.6,34.9,32.8,31.8,30.2,28.6,22.8.HRMS(EI):calcd For[C 33 H 41 N8O6](M+H) + ,691.3362;found,691.3378.

[0145] Embodiment 14

[0146] Compound 10a was prepared by the following synthetic route:

[0147]

[0148] The specific steps are:

[0149] (1) Compound 7 (118 mg, 0.40 mmol) and compound 2a (39 mg, 0.45 mmol) were weighed and dissolved in anhydrous DMF (5 mL), and DIPEA (0.23 mL, 1.35 mmol) was added. The reaction solution was heated to 100°C and stirred for 5 h. The reaction was monitored by TLC. After the reaction was completed, the mixture was cooled to room temperature, saturated saline and dichloromethane were added, and the organic phases were combined. The residue 8a was distilled under reduced pressure and used in the next step without purification. 8a was dissolved in dichloromethane (10 mL), Dess-Martin oxidant (0.25 g, 0.60 mmol) was slowly added, and the reaction was continued at room temperature for 1 h. After the reaction was completed, saturated sodium sulfite solution was added, stirred for 10 min, the organic phase was separated, concentrated, and purified by column chromatography (DCM / MeOH=50:1 to 25:1) to obtain yellow compound 9a.

[0150] (2) Compound 9a (36 mg, 0.10 mmol) and compound 5 (22 mg, 0.10 mmol) were weighed and dissolved in a mixed solvent of DCM / MeOH (5:1, v / v), cooled to 5°C, and a few drops of HOAc were added. After the reaction solution was stirred for 10 minutes, Na(AcO)3BH (64 mg, 0.3 mmol) was added. The temperature was slowly returned to room temperature and the reaction was continued to stir for 12-14 hours. Saturated NaHCO3 solution was added to the reaction, stirred for 5 minutes, extracted with dichloromethane, the organic phases were combined, concentrated, and purified by column (DCM / MeOH = 50:1 to 25:1) to obtain yellow compound 10a.

[0151] 1-(2-(2,6-Dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)azetidine-3-carbaldehyde(9a).Yellowish solid(116mg, 81%). 1 HNMR (600MHz, DMSO-d6): δ11.11(s,1H),9.85(s,1H),7.98-8.02(m,1H),7.72-7.73(m,1H),5.06-5.11(m,1H),4.32-4.3 3(m,2H),3.96-4.01(m,1H),3.04-3.05(m,1H),2.85-2.91(m,1H),2.53-2.62(m,2H),2.00-2.05(m,2H).HRMS(EI):calcd For[C 17 H 15 FN3O5](M+H) +,360.0990;found,360.0985.

[0152] 5-(3-((4-(3-Amino-4-nitrophenyl)piperazin-1-yl)methyl)azetidin-1-yl)-2-(2,6-dioxopiperidin-3-yl)-6-fluoroisoindoline-1,3-dione(10a). Yellowishsolid (36 mg, 64%). 1 HNMR (600MHz, DMSO-d6): δ11.09(s,1H),7.81(d,J=8.0Hz,1H),7.60(d,J=8.0 Hz,1H),7.27(s,1H),6.92(d,J=8.0Hz,1H),6.39-6.42(m,1H),6.21-6.22(m,1 H),5.05-5.08(m,1H),4.28-4.30(m,2H),3.85-3.87(m,2H),3.01-3.03(m,1H) ,2.86-2.91(m,1H),2.66-2.67(m,2H),2.51-2.60(m,10H),2.00-2.04(m,1H). 13 C NMR (150MHz, DMSO-d6): δ173.2, 170.5, 167.3, 166.8, 155.4 (d, J = 206.3Hz), 154.1, 148.8, 144.6 (d, J = 10.0Hz), 129.8, 1 27.6,123.4,118.8,111.7(10.0Hz),108.4,105.8,97.9,61.8,58.1,52.8,49.4,46.6,31.4,28.2,22.6.HRMS(EI):calcd For[C 27 H 29 FN7O6](M+H) + ,566.2158;found,566.2164.

[0153] Embodiment 15

[0154] Compound 10b was prepared, and its structural formula is as follows:

[0155]

[0156] Referring to the method in Example 14, compound 7 was reacted with pyrrolidin-3-ylmethanol to synthesize intermediate 9b; intermediate 9b was then reacted with compound 5 to obtain compound 10b, a total of 35 mg, with a yield of 61%, and a yellow solid powder.

[0157] 1-(2-(2,6-Dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)pyrrolidine-3-carbaldehyde(9b).Yellowish solid(119 mg, 80%). 1 HNMR (600MHz, DMSO-d6): δ11.11(,1H),9.70(s,1H),7.63-7.66(m,1H),7. 10-7.12(m,1H),5.07-5.10(m,1H),3.90-3.93(m,1H),3.70-3.72(m,1H),3 .45-3.51(m,3H),3.18-3.19(m,1H),2.87-2.92(m,2H),2.54-2.61(m,2H) ,2.27-2.28(m,1H),2.20-2.22(m,1H),2.01-2.05(m,2H).HRMS(EI):calcd For[C 18 H 17 FN3O5](M+H) + ,374.1147;found,374.1150.

[0158] 5-(3-((4-(3-Amino-4-nitrophenyl)piperazin-1-yl)methyl)pyrrolidin-1-yl)-2-(2,6-dioxopiperidi n-3-yl)-6-fluoroisoindoline-1,3-dione(10b). Yellowishsolid (35 mg, 61%). 1HNMR (600MHz, DMSO-d6): δ11.09(s,1H),7.81(d,J=8.0Hz,1H),7.59(d,J=8 .0Hz,1H),7.27(s,2H),7.04-7.05(m,1H),6.39-6.41(m,1H),6.22(s,1H),5 .05-5.09(m,1H),3.61-3.72(m,4H),3.31-3.33(m,2H),2.86-2.92(m,1H), 2.47-2.61(m,9H),2.38-2.43(m,2H),2.00-2.11(m,2H),1.69-1.73(m,1H). 13 C NMR (150MHz, DMSO-d6): δ173.2, 170.5, 167.4, 166.8, 155.4, 153.5 (d, J = 205.0Hz), 148.8, 142.3 (d, J = 7.5Hz), 130.0, 127.6, 123.3 ,117.5(d,J=7.5Hz),112.2,112.1,109.6,105.8,97.8,61.0,54.7,53.0,49.8,49.3,46.7,35.8,31.4,29.7,22.6.HRMS(EI):calcd For[C 28 H 31 FN7O6](M+H) + ,580.2314;found,580.2320.

[0159] Example 16

[0160] Compound 10c was prepared, and its structural formula is as follows:

[0161]

[0162] Referring to the method in Example 1, compound 7 was reacted with piperidin-4-ylmethanol to synthesize intermediate 9c; intermediate 9c was then reacted with compound 5 to obtain compound 10c, a total of 35 mg, with a yield of 61%, and a yellow solid powder.

[0163] 1-(2-(2,6-Dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)piperidine-4-carbaldehyde(9c).Yellowish solid(117mg,76%). 1HNMR(600MHz,DMSO-d6):δ11.13(s,1H),9.66(s,1H),7.73-7.75(m,1H),7.47-7.49(m,1H),3.54-3.57(m,2H),3.02-3.06(m,2H),2.88-2.92(m,2H),2.52-2.60(m,4H),1.99-2.07(m,2H),1.65-1.70(m,2H).HRMS(EI):calcd For[C 19 H 19 FN3O5](M+H) + ,388.1303;found,388.1305.

[0164] 5-(4-((4-(3-Amino-4-nitrophenyl)piperazin-1-yl)methyl)piperidin-1-yl)-2-(2,6-dioxopiperidin-3-yl)-6-fluoroisoindoline-1,3-dione(10c).Yellowishsolid(34mg,57%). 1 HNMR(600MHz,DMSO-d6):δ11.12(s,1H),7.81(d,J=8.0Hz,1H),7.71(d,J=8.0Hz,1H),7.44-7.45(m,1H),7.27(s,2H),6.39-6.41(m,1H),6.22(s,1H),5.09-5.12(m,1H),3.61-3.63(m,2H),3.32-3.35(m,4H),2.86-2.92(m,3H),2.53-2.62(m,2H),2.46-2.48(m,4H),2.23-2.24(m,2H),2.02-2.06(m,1H),1.84-1.86(m,2H),1.76-1.79(m,1H),1.25-1.32(m,2H). 13C NMR (150MHz, DMSO-d6): δ173.2,170.4,167.2,166.7,157.7(d,J=210.0Hz),155.4,148.8,146.3(d,J=7.5Hz),129.2,127.6,123.3 ,123.2(d,J=7.5Hz),114.1,112.4,112.2,105.8,97.8,64.1,60.2,53.2,50.3,49.5,46.7,32.6,31.4,30.7,22.5.HRMS(EI):calcd For[C 29 H 33 FN7O6](M+H) + ,594.2471;found,594.2482.

[0165] Embodiment 17

[0166] Compound 10d was prepared, and its structural formula is as follows:

[0167]

[0168] Referring to the method in Example 14, compound 7 was reacted with piperidin-3-ylmethanol to synthesize intermediate 9d; intermediate 9d was then reacted with compound 5 to obtain compound 10d, a total of 31 mg, with a yield of 53%, and a yellow solid powder.

[0169] 1-(2-(2,6-Dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)piperidine-3-carbaldehyde(9d).Yellowish solid(115mg,74%). 1 HNMR (600MHz, DMSO-d6): δ11.12(s,1H),9.69(s,1H),7.73-7.75(m,1H),7.51-7.52 (m,1H),5.10-5.13(m,1H),3.53-3.56(m,1H),3.37-3.40(m,2H),3.27-3.30(m,1H), 3.07-3.11(m,1H),2.86-2.92(m,1H),2.69-2.72(m,1H),2.58-2.62(m,1H),2.02-2. 07(m,1H),1.86-1.92(m,1H),1.70-1.76(m,2H),1.64-1.68(m,1H).HRMS(EI):calcd For[C19 H 19 FN3O5](M+H) + ,388.1303; found, 388.1303.

[0170] 5-(3-((4-(3-Amino-4-nitrophenyl)piperazin-1-yl)methyl)piperidin-1-yl)-2-(2,6-dioxopiperidin-3-yl)-6-fluoroisoindoline-1,3-dione (10d). Yellowish solid (31 mg, 53%). 1 HNMR (600 MHz, DMSO-d6): δ 11.11 (s, 1H), 7.81 (d, J = 8.0 Hz, 1H), 7.71 (d, J = 8.0 Hz, 1H), 7.44 - 7.45 (m, 1H), 7.27 (s, 2H), 6.39 - 6.41 (m, 1H), 6.22 (s, 1H), 5.09 - 5.12 (m, 1H), 3.64 - 3.66 (m, 1H), 3.51 - 3.54 (m, 1H), 2.86 - 2.97 (m, 2H), 2.69 - 2.72 (m, 1H), 2.58 - 2.62 (m, 1H), 2.49 - 2.56 (m, 6H), 2.39 - 2.43 (m, 2H), 2.30 - 2.34 (m, 1H), 2.19 - 2.22 (m, 1H), 1.96 - 2.06 (m, 2H), 1.76 - 1.83 (m, 2H), 1.63 - 1.67 (m, 1H), 1.15 - 1.21 (m, 1H), 0.82 - 0.86 (m, 1H). 13 C NMR (150 MHz, DMSO-d6): δ 173.2, 170.4, 167.2, 166.7, 157.6 (d, J = 210.0 Hz), 155.4, 148.8, 146.4 (d, J = 7.5 Hz), 129.3, 127.6, 123.4, 123.1 (d, J = 7.5 Hz), 114.1, 112.5, 112.3, 105.8, 97.8, 61.4, 55.1, 53.2, 51.0, 49.5, 46.7, 33.2, 31.4, 28.8, 24.7, 22.6. HRMS (EI): calcd For [C 29 H 33 FN7O6](M+H) + ,594.2471; found, 594.2505.

[0171] Example 18

[0172] Compound 10e was prepared, and its structural formula is as follows:

[0173]

[0174] Referring to the method in Example 14, compound 7 was reacted with 2-(piperidin-4-yl)ethan-1-ol to synthesize intermediate 9e; intermediate 9e was then reacted with compound 5 to obtain compound 10e, a total of 33 mg, with a yield of 55%, as a yellow solid powder.

[0175] 2-(1-(2-(2,6-Dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)piperidin-4-yl)acetaldehyde(9e). Yellowish solid (132 mg, 82%). 1 HNMR (600MHz, DMSO-d6): δ11.12(s,1H),9.71(s,1H),7.69-7.71(m,1H),7.44-7.45(m,1H),5.09-5.12(m,1H),3.57-3.60(m,2H), 2.86-2.94(m,3H),2.54-2.62(m,2H),2.44-2.51(m,2H),2.02-2.06(m,2H),1.76-1.79(m,2H),1.34-1.38(m,2H).HRMS(EI):calcd For[C 20 H 21 FN3O5](M+H) + ,402.1460;found,402.1460.

[0176] 5-(4-(2-(4-(3-Amino-4-nitrophenyl)piperazin-1-yl)ethyl)piperidin-1-yl)-2-(2,6-dioxopiperidin-3-yl)-6-fluoroisoindoline-1,3-dione(10e). Yellowishsolid (33 mg, 55%). 1HNMR (600MHz, DMSO-d6): δ11.12(s,1H),7.81(d,J=8.0Hz,1H),7.71(d,J=8.0Hz,1H),7.45 (d,J=8.0Hz,1H),7.27(s,2H),6.39-6.41(m,1H),6.21(s,1H),5.09-5.12(m,1H),3.55-3. 61(m,2H),2.86-2.91(m,3H),2.61-2.62(m,1H),2.37-2.54(m,8H),2.36-2.49(m,2H),2.0 0-2.05(m,1H),1.80-1.82(m,2H),1.52-1.54(m,1H),1.45-1.48(m,2H),1.30-1.36(m,2H). 13 C NMR (150MHz, DMSO-d6): δ173.2,170.4,167.2,166.7,157.7(d,J=210.0Hz),155.4,148.8,146.3(d,J=7.5Hz),129.3,127.6,123.4 ,123.3(d,J=7.5Hz),114.2,112.4,112.2,105.8,97.8,55.6,52.9,50.6,49.5,46.7,33.5,33.2,32.2,31.4,22.5.HRMS(EI):calcd For[C 30 H 35 FN7O6](M+H) + ,608.2627;found,608.2555.

[0177] Embodiment 19

[0178] Compound 10f was prepared, and its structural formula is as follows:

[0179]

[0180] Referring to the method in Example 14, compound 7 was reacted with 3-(piperidin-4-yl)propan-1-ol to synthesize intermediate 9f; intermediate 9f was then reacted with compound 5 to obtain compound 10f, a total of 38 mg, with a yield of 63%, a yellow solid powder.

[0181] 3-(1-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)piperidin-4-yl)propanal(9f).Yellowish solid(133mg,80%). 1 HNMR(600MHz,DMSO-d6):δ11.11(s,1H),9.71(s,1H),7.70-7.72(m,1H),7.43-7.45(m,1H),5.09-5.12(m,1H),3.59-3.62(m,2H),2.83-2.92(m,3H),2.54-2.62(m,1H),2.51-2.54(m,3H),2.02-2.05(m,1H),1.76-1.79(m,2H),1.52-1.55(m,2H),1.43-1.46(m,1H),1.27-1.31(m,2H).HRMS(EI):calcd For[C 21 H 23 FN3O5](M+H) + ,416.1616;found,416.1620.

[0182] 5-(4-(3-(4-(3-Amino-4-nitrophenyl)piperazin-1-yl)propyl)piperidin-1-yl)-2-(2,6-dioxopiperidi n-3-yl)-6-fluoroisoindoline-1,3-dione(10f).Yellowishsolid(38mg,63%). 1 HNMR(600MHz,DMSO-d6):δ11.12(s,1H),7.81(d,J=8.0Hz,1H),7.70(d,J=8.0Hz,1H),7.43-7.45(m,1H),7.27(s,2H),6.38-6.41(m,1H),6.22(s,1H),5.09-5.13(m,1H),3.60-3.62(m,4H),2.85-2.92(m,4H),2.55-2.62(m,3H),2.46-2.53(m,3H),2.30-2.33(m,2H),2.02-2.05(m,1H),1.79-1.81(m,2H). 13C NMR (150MHz, DMSO-d6): δ173.2,170.4,167.1,166.7,157.7(d,J=208.7Hz),155.4,148.8,146.3(d,J=7.6Hz),129.2,127.6,123.3,12 3.2(d,J=7.6Hz),114.1,112.4,112.2,105.8,97.8,58.4,52.8,50.6,49.5,46.7,35.2,34.2,32.2,31.4,23.8,22.5.HRMS(EI):calcd For[C 31 H 37 FN7O6](M+H) + ,622.2784;found,622.2827.

[0183] Embodiment 20

[0184] Prepare compound 10g, whose structural formula is as follows:

[0185]

[0186] Referring to the method in Example 14, compound 7 was reacted with (3-azabicyclo[3.1.0]hexan-6-yl)methanol to synthesize intermediate 9g; intermediate 9g was then reacted with compound 5 to obtain compound 10g, a total of 39 mg, with a yield of 68%, and a yellow solid powder.

[0187] 3-(2-(2,6-Dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)-3-azabicyclo[3.1.0]hexane-6-carbaldehyde(9g).Yellowish solid(134mg, 87%). 1 HNMR (600MHz, DMSO-d6): δ11.10(s,1H),9.17(d,J=6.0Hz,1H),7.63-7.65(m,1H),7.11-7.13(m,1H),5.06-5.09(m,1H),3.92-3.94(m, 2H),3.69-3.71(m,2H),2.85-2.91(m,1H),2.57-2.61(m,1H),2.51-2.53(m,3H),2.00-2.04(m,1H),1.86-1.88(m,1H).HRMS(EI):calcd For[C 19 H 17FN3O5](M+H) + ,386.1147;found,386.1148.

[0188] 5-(6-((4-(3-Amino-4-nitrophenyl)piperazin-1-yl)methyl)-3-azabicyclo[3.1.0]hexan-3-yl)-2-(2,6-dioxopiperidin-3-yl)-6-fluoroisoindoline-1,3-dione (10g). Yellowish solid (39mg, 68%). 1 HNMR (600MHz, DMSO-d6): δ11.10(s,1H),7.81(d,J=8.0Hz,1H),7.70(d,J=8.0Hz,1H), 6.90-6.93(m,1H),6.79-6.82(m,1H),6.38-6.40(m,1H),6.22(s,1H),5.06-5.08(m,1H ),3.68-3.70(m,2H),3.45-3.46(m,3H),2.85-2.94(m,1H),2.48-2.60(m,8H),2.34-2. 35(m,2H),2.00-2.04(m,1H),1.65-1.70(m,2H),0.82-0.86(m,1H),0.76-0.79(m,1H). 13 C NMR (150MHz, DMSO-d6): δ173.2,170.4,167.9,167.7,157.8(d,J=208.9Hz),155.6,148.8,146.5(d,J=7.6Hz),128.6,127.3, 123.3,123.0(d,J=7.6Hz),116.3,106.5,105.9,97.8,58.9,55.6,51.8,50.9,49.4,46.8,31.6,22.8,22.6.HRMS(EI):calcd For[C 29 H 31 FN7O6](M+H) + ,592.2314;found,592.2326.

[0189] Embodiment 21

[0190] Compound 10h was prepared, and its structural formula is as follows:

[0191]

[0192] Referring to the method in Example 14, compound 7 was reacted with (4-fluoropiperidin-4-yl)methanol to synthesize intermediate 9h; intermediate 9h was then reacted with compound 5 to obtain compound 10h, a total of 26 mg, a yield of 42%, and a yellow solid powder.

[0193] 1-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)-4-fluoropiperidine-4-carbal dehyde(9h). Yellowish solid(116mg, 72%). 1 HNMR (600MHz, DMSO-d6): δ11.13(s,1H),9.66(s,1H),7.74-7.75(m,1H),7.47-7.50(m,1H),3.55-3.58(m,2H), 3.02-3.06(m,2H),2.90-2.92(m,2H),2.51-2.60(m,3H),1.99-2.06(m,2H),1.66-1.70(m,2H).HRMS(EI):calcd For[C 19 H 18 F2N3O5](M+H) + ,406.1209;found,406.1214.

[0194] 5-(4-((4-(3-amino-4-nitrophenyl)piperazin-1-yl)methyl)-4-fluoropiperidin-1-yl)-2-(2,6-dioxo piperidin-3-yl)-6-fluoroisoindoline-1,3-dione (10h). Yellowish solid (26mg, 42%). 1HNMR (600MHz, DMSO-d6): δ11.11(s,1H),7.81(d,J=8.0Hz,1H),7.72(d,J=8.0Hz,1H),7.4 4-7.46(m,1H),7.27(s,2H),6.39-6.40(m,1H),6.22(s,1H),5.09-5.12(m,1H),3.61-3.64 (m,2H),3.34-3.36(m,4H),2.86-2.92(m,3H),2.55-2.60(m,2H),2.47-2.49(m,3H),2.23 -2.24(m,2H),2.02-2.06(m,1H),1.84-1.86(m,2H),1.76-1.80(m,1H),1.25-1.32(m,2H). 13 C NMR (150MHz, DMSO-d6): δ173.4,170.6,167.2,166.7,157.8(d,J=210.1Hz),155.4,148.8,146.4(d,J=7.6Hz),129.2,127.6,123.9 ,123.4(d,J=7.5Hz),114.0,112.7,112.4,105.8,97.8,64.1,60.5,53.2,50.3,49.5,46.8,32.6,31.4,30.8,22.5.HRMS(EI):calcd For[C 29 H 33 FN7O6](M+H) + ,594.2471;found,574.2426.

[0195] Embodiment 22

[0196] Compound 10i was prepared, and its structural formula is as follows:

[0197]

[0198] Referring to the method in Example 14, compound 7 was reacted with [1,4'-bipiperidin]-4-ylmethanol to synthesize intermediate 9i; intermediate 9i was then reacted with compound 5 to obtain compound 10i, a total of 33 mg, with a yield of 49%, and a yellow solid powder.

[0199] 1'-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)-[1,4'-bipiperidine]-4-carba ldehyde(9i).Yellowish solid(113mg,60%). 1 HNMR(600MHz,DMSO-d6):δ11.09(s,1H),9.65(s,1H),7.38(s,1H),7.29(s,1H),5.06-5.10(m,1H),3.89-3.98(m,4H),3.10-3.22(m,8H),2.89-2.91(m,3H),2.56-2.62(m,4H),2.01-2.04(m,1H),1.80-1.97(m,6H),1.45-1.59(m,4H).HRMS(EI):calcd For[C 24 H 28 FN4O5](M+H) + ,471.2038;found,471.2048.

[0200] 5-(4-((4-(3-amino-4-nitrophenyl)piperazin-1-yl)methyl)-[1,4'-bipiperidin]-1'-yl)-2-(2,6-dioxo piperidin-3-yl)-6-fluoroisoindoline-1,3-dione(10i).Yellowish solid(33mg,49%). 1 HNMR(600MHz,DMSO-d6):δ11.09(s,1H),7.81(d,J=8.0Hz,1H),7.69(d,J=8.0Hz,1H),7.26-7.30(m,2H),7.24-7.27(m,1H),6.36-6.41(m,1H),6.21(s,1H),5.08-5.12(m,1H),4.04-4.08(m,2H),3.32-3.70(m,7H),3.12-3.14(m,4H),2.97(t,J=6.0Hz,2H),2.87-2.90(m,1H),2.55-2.64(m,4H),2.46-2.50(m,4H),2.19(d,J=6.0Hz,2H),2.02-2.06(m,2H),1.84-1.90(m,7H),1.16-1.43(m,4H). 13C NMR (150MHz, DMSO-d6): δ173.4,170.6,168.2,168.0,155.4,149.1,134.6,128.2,125.8,124.0,118.0,117.8,108.4, 105.9,98.2,64.2,53.4,49.2,47.8,46.8,46.6,46.0,34.8,34.7,32.9,31.6,30.0,28.2,28.1,22.8.HRMS(EI):calcd For[C 34 H 42 FN8O6](M+H) + ,677.3206;found,677.3224.

[0201] Embodiment 23

[0202] Compound 10j was prepared, and its structural formula is as follows:

[0203]

[0204] Referring to the method in Example 14, compound 7 was reacted with 1-(azetidin-3-yl)piperidin-4-yl)methanol to synthesize intermediate 9j; intermediate 9j was then reacted with compound 5 to obtain compound 10j, a total of 31 mg, with a yield of 48%, as a yellow solid powder.

[0205] 1-(1-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)azetidin-3-yl)piperidine-4-carbaldehyde(9j).Yellowish solid(115mg, 65%). 1 HNMR (600MHz, DMSO-d6): δ11.11(s,1H),9.86(s,1H),7.98-8.02(m,1H),7.72-7.73(m,1H),5.06-5.12(m,1H),4.31-4.34(m,2H),3.96-4.0 1(m,1H),3.12-3.14(m,4H),3.04-3.06(m,1H),2.85-2.91(m,1H),2.53-2.64(m,3H),2.00-2.05(m,2H),1.43-1.44(m,2H).HRMS(EI):calcd For[C 22 H 24 FN4O5](M+H)+ ,443.1725;found,443.1780.

[0206] 5-(3-(4-((4-(3-amino-4-nitrophenyl)piperazin-1-yl)methyl)piperidin-1-yl)azetidin-1-yl)-2-(2,6-dioxopiperidin-3-yl)-6-fluoroisoindoline-1,3-dione(10j). Yellowish solid (31 mg, 48%). 1 HNMR (600MHz, DMSO-d6): δ11.09(s,1H),7.82(d,J=8.0Hz,1H),7.60(d,J=8.0Hz,1H),7 .28(s,1H),6.92(d,J=8.0Hz,1H),6.40-6.44(m,1H),6.21-6.22(m,1H),5.04-5.08(m,1 H),4.28-4.30(m,2H),3.84-3.86(m,2H),3.11-3.15(m,4H),3.01-3.04(m,1H),2.86-2. 91(m,1H),2.66-2.68(m,2H),2.51-2.63(m,11H),2.00-2.06(m,1H),1.41-1.43(m,2H). 13 C NMR (150MHz, DMSO-d6): δ173.2,170.6,167.3,166.9,155.6(d,J=206.3Hz),154.1,148.9,144.8(d,J=10.0Hz),129.8,128.6,123 .4,119.4,111.7(10.0Hz),108.4,106.0,97.9,61.9,58.4,52.8,49.4,46.6,46.2,34.8,31.4,28.4,28.1,22.8.HRMS(EI):calcd For[C 32 H 38 FN8O6](M+H) + ,649.2893;found,649.2898.

[0207] Embodiment 24

[0208] Compound 10k was prepared, and its structural formula is as follows:

[0209]

[0210] Referring to the method in Example 14, compound 7 was reacted with (1-(piperidin-4-ylmethyl)piperidin-4-yl)methanol to synthesize intermediate 9k; intermediate 9k was then reacted with compound 5 to obtain compound 10k, a total of 35 mg, with a yield of 51%, and a yellow solid powder.

[0211] 1-((1-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)piperidin-4-yl)methyl)pi peridine-4-carbaldehyde(9k). Yellowish solid (191 mg, 74%). 1 HNMR (600MHz, DMSO-d6): δ11.09(s,1H),9.66(s,1H),7.40(s,1H),7.29(s,1H),5.06-5.10(m,1H),3.90-3.99(m,4H),3.10- 3.22(m,8H),2.90-2.92(m,3H),2.58-2.62(m,4H),2.01-2.09(m,3H),1.80-1.97(m,6H),1.46-1.60(m,4H).HRMS(EI):calcd For[C 25 H 30 FN4O5](M+H) + ,485.2195;found,485.2200.

[0212] 5-(4-((4-((4-(3-amino-4-nitrophenyl)piperazin-1-yl)methyl)piperidin-1-yl)methyl)

[0213] piperidin-1-yl)-2-(2,6-dioxopiperidin-3-yl)-6-fluoroisoindoline-1,3-dione(10k). Yellowish solid(35mg, 51%). 1HNMR (600MHz, DMSO-d6): δ11.09(s,1H),7.82(d,J=8.0Hz,1H),7.70(d,J=8.0Hz,1H),7.26-7.30( m,2H),7.26-7.28(m,1H),6.36-6.41(m,1H),6.21(s,1H),5.08-5.12(m,1H),4.05-4.09(m,2H),3 .32-3.70(m,7H),3.13-3.15(m,4H),2.98(t,J=6.0Hz,2H),2.87-2.90(m,1H),2.56-2.65(m,4H), 2.46-2.50(m,4H),2.20(d,J=6.0Hz,2H),2.03-2.10(m,4H),1.84-1.90(m,7H),1.17-1.43(m,4H). 13 C NMR (150MHz, DMSO-d6): δ173.6,170.6,168.4,168.0,155.6,149.2,134.6,128.5,125.8,124.1,118.0,117.9,108.4,105 .9,98.5,64.2,61.9,53.6,49.1,47.8,46.9,46.4,46.2,35.2,34.8,32.9,32.0,30.0,28.4,28.1,22.9.HRMS(EI):calcd For[C 35 H 44 FN8O6](M+H) + ,691.3362;found,691.3375.

[0214] Embodiment 25

[0215] Compound 101 was prepared, and its structural formula is as follows:

[0216]

[0217] Referring to the method in Example 14, compound 7 was reacted with (1-(piperidin-4-ylmethyl)azetidin-3-yl)methanol to synthesize intermediate 9l; intermediate 9l was then reacted with compound 5 to obtain compound 10l, a total of 30 mg, with a yield of 46%, and a yellow solid powder.

[0218] 1-((1-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)piperidin-4-yl)methyl)az etidine-3-carbaldehyde(9l).Yellowish solid(111mg,61%). 1 HNMR(600MHz,DMSO-d6):δ11.10(s,1H),9.86(s,1H),7.99-8.02(m,1H),7.71-7.74(m,1H),5.06-5.12(m,1H),4.32-4.36(m,2H),3.96-4.01(m,1H),3.12-3.14(m,4H),3.05-3.07(m,1H),2.86-2.92(m,1H),2.53-2.64(m,3H),2.01-2.12(m,4H),1.42-1.46(m,2H).HRMS(EI):calcd For[C 23 H 26 FN4O5](M+H) + ,457.1882;found,457.1874.

[0219] 5-(4-((3-((4-(3-amino-4-nitrophenyl)piperazin-1-yl)methyl)azetidin-1-yl)methyl)

[0220] piperidin-1-yl)-2-(2,6-dioxopiperidin-3-yl)-6-fluoroisoindoline-1,3-dione(10l).Yellowish solid(30mg,46%). 1HNMR (600MHz, DMSO-d6): δ11.09(s,1H),7.83(d,J=8.0Hz,1H),7.61(d,J=8.0Hz,1H),7 .28(s,1H),6.93(d,J=8.0Hz,1H),6.40-6.44(m,1H),6.20-6.23(m,1H),5.05-5.09(m,1 H),4.28-4.30(m,2H),3.84-3.86(m,2H),3.12-3.16(m,4H),3.01-3.04(m,1H),2.87-2. 90(m,1H),2.65-2.67(m,2H),2.51-2.63(m,11H),2.01-2.11(m,3H),1.41-1.43(m,2H). 13 C NMR (150MHz, DMSO-d6): δ173.2, 170.8, 167.4, 166.9, 155.8 (d, J = 206.3Hz), 154.2, 148.9, 144.8 (d, J = 10.0Hz), 123.0, 128.6, 124.6 ,120.1,111.8(10.0Hz),108.4,106.3,97.9,62.0,61.9,58.4,52.9,49.5,46.6,46.3,34.8,31.5,28.6,28.1,22.9.HRMS(EI):calcd For[C 33 H 40 FN8O6](M+H) + ,663.3049;found,663.3055.

[0221] Embodiment 26

[0222] Compound 10m was prepared, and its structural formula is as follows:

[0223]

[0224] Referring to the method in Example 14, compound 7 was reacted with (1-((4-fluoropiperidin-4-yl)methyl)piperidin-4-yl)methanol to synthesize intermediate 9m; intermediate 9m was then reacted with compound 5 to obtain compound 10m, a total of 40 mg, with a yield of 57%, and a yellow solid powder.

[0225] 1-((1-(2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindolin-5-yl)-4-fluoropiperidin-4-yl)methyl)piperidine-4-carbaldehyde(9m).Yellowishsolid(110mg,55%). 1 HNMR(600MHz,DMSO-d6):δ11.10(s,1H),9.67(s,1H),7.74-7.75(m,1H),7.46-7.51(m,1H),3.53-3.56(m,2H),3.00-3.04(m,2H),2.89-2.91(m,2H),2.51-2.60(m,3H),2.00-2.12(m,4H),1.66-1.70(m,2H).HRMS(EI):calcd For[C 25 H 29 F2N4O5](M+H) + ,503.2101;found,503.2136.

[0226] 5-(4-((4-((4-(3-amino-4-nitrophenyl)piperazin-1-yl)methyl)piperidin-1-yl)methyl)-4-fluoropi peridin-1-yl)-2-(2,6-dioxopiperidin-3-yl)-6-fluoroisoindoline-1,3-dione(10m).Yellowish solid(40mg,57%). 1HNMR (600MHz, DMSO-d6): δ11.08(s,1H),7.85(d,J=8.0Hz,1H),7.70(d,J=8.0Hz,1H),7.24-7.28( m,2H),7.26-7.28(m,1H),6.36-6.41(m,1H),6.23(s,1H),5.09-5.12(m,1H),4.05-4.09(m,2H),3 .34-3.69(m,7H),3.12-3.16(m,4H),2.99(t,J=6.0Hz,2H),2.88-2.91(m,1H),2.56-2.65(m,4H), 2.46-2.50(m,4H),2.19(d,J=6.0Hz,2H),2.06-2.10(m,4H),1.85-1.89(m,7H),1.18-1.44(m,3H). 13 C NMR (150MHz, DMSO-d6): δ173.6,170.8,168.4,168.1,155.6,149.2,134.7,128.6,125.8,124.3,118.0,117.9,108.4,106 .0,98.5,64.2,61.9,53.8,49.1,47.9,46.6,46.3,46.2,35.0,34.8,32.9,32.6,30.1,28.4,28.3,22.9.HRMS(EI):calcd For[C 35 H 43 F2N8O6](M+H) + ,709.3268;found,709.3277.

[0227] Embodiment 27

[0228] Compound 12a was prepared by the following synthetic route:

[0229]

[0230] Further, according to the difference of intermediate compound 4a, for example, by selecting intermediate compounds 4a-4g and 9a-9g in the above embodiment, compounds 12a-12g and 13a-13g can be synthesized. The synthesis process of intermediate compounds 4a-4g and 9a-9g is not described in detail in the following embodiments.

[0231]

[0232] This example takes the synthesis of compound 12a as an example to introduce the specific synthesis steps:

[0233] (1) Synthesis of Compound 11

[0234] Compound 5 (44 mg, 0.2 mmol) and tert-butyl (2-oxoethyl) carbamate (32 mg, 0.2 mmol) were dissolved in 2 mL of dichloromethane, 10 drops of acetic acid were added, and the mixture was stirred at room temperature for 10 minutes. The reaction solution was then cooled to 5°C, sodium triethoxyborohydride (127 mg, 0.6 mmol) was slowly added, stirred for 10 minutes, and the mixture was returned to room temperature and the reaction was continued for 18 hours. Trifluoroacetic acid was slowly added to the reaction solution, and the mixture was reacted at room temperature for 30 minutes. The mixture was extracted with ethyl acetate and purified by column to obtain compound 11 (42 mg) with a yield of 78%.

[0235] The structure of compound 11a is as follows:

[0236]

[0237] 5-(4-(2-aminoethyl)piperazin-1-yl)-2-nitroaniline(11): 1 HNMR(600MHz,d6-DMSO):7.80(d,J=6.4Hz,1H),7.26(s,2H),6.70(t,J=6.4Hz,1H),6.39-6.41(m,1H),6.2 1(d,J=6.0Hz,1H),3.30-3.31(m,4H),3.07-3.08(m,2H),2.48-2.51(m,2H),2.35-2.37(m,2H),1.5(s,2H).

[0238] (2) Synthesis of compound 12a

[0239] The structure of compound 12a is as follows:

[0240]

[0241] Referring to the method of step (2) in Example 1, compound 11 was reacted with 4a to obtain compound 12a, a total of 46 mg, with a yield of 78%, as a yellow solid powder.

[0242] 5-(3-(((2-(4-(3-amino-4-nitrophenyl)piperazin-1-yl)ethyl)amino)methyl)azetidin-1-yl)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione(12a). Yellowish solid (46 mg, 78%). 1HNMR(600MHz,DMSO-d6):δ11.08(br s,1H),7.82(d,J=8.0Hz,1H),7.66(d,J=8.0Hz,1H),7.27(s,2H),6.80(s ,1H),6.66–6.67(m,1H),6.40–6.42(m,1H),6.23–6.24(m,1H),5.05–5.08 (m,1H),4.16(t,J=6.0Hz,1H),3.79–3.82(m,1H),3.35–3.50(m,11H),2. 86–3.15(m,4H),2.49–2.62(m,4H),2.00–2.03(m,1H),1.24–1.25(m,1H); 13 C NMR (150MHz, DMSO-d6): δ173.3,170.6,167.9,155.6,155.4,148.8,134.3,127.6,125.3,123.4,114.6, 105.8,104.8,97.9,72.7,60.7,55.5,52.6,51.3,49.2,46.6,31.5,29.3,22.7.HRMS(EI):calcd.for[C 29 H 35 N8O6](M+H) + ,591.2674;found,591.2687.

[0243] Embodiment 28

[0244] Compound 12b was prepared, and its structural formula is as follows:

[0245]

[0246] Referring to the method of step (2) in Example 1, compound 11 was reacted with compound 4b to obtain compound 12b, a total of 44 mg, with a yield of 73%, as a yellow solid powder.

[0247] 5-(3-(((2-(4-(3-amino-4-nitrophenyl)piperazin-1-yl)ethyl)amino)methyl)

[0248] pyrrolidin-1-yl)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione(12b). Yellowish solid (44 mg, 73%). 1HNMR(600MHz,DMSO-d6):δ11.08(br s,1H),7.82(d,J=8.0Hz,1H),7.67(d,J=8.0Hz,1H),7.27(s,2H),6.92(s,1H ),6.81–6.82(m,1H),6.40–6.42(m,1H),6.22–6.23(m,1H),5.05–5.08(m,1H) ,3.43–3.61(m,6H),3.20–3.36(m,5H),2.80–2.93(m,3H),2.54–2.64(m,8H) ,2.17–2.20(m,1H),2.00–2.04(m,1H),1.79–1.83(m,1H),1.25–1.28(m,1H); 13 C NMR (150MHz, DMSO-d6): δ173.2,170.6,168.2,167.7,155.4,152.2,148.8,134.5,127.6,125.5,123.4,116.0,115.7 ,105.9,105.8,97.9,52.8,52.3,49.1,47.7,47.1,46.8,46.6,45.9,31.5,29.5,27.0,22.7.HRMS(EI):calcd.for[C 30 H 37 N8O6](M+H) + ,605.2831;found,605.2847.

[0249] Embodiment 29

[0250] Compound 12c was prepared, and its structural formula is as follows:

[0251]

[0252] Referring to the method of step (2) in Example 1, compound 11 was reacted with compound 4c to obtain compound 12c, a total of 41 mg, with a yield of 67%, as a yellow solid powder.

[0253] 5-(4-(((2-(4-(3-amino-4-nitrophenyl)piperazin-1-yl)ethyl)amino)methyl)piperidin-1-yl)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione(12c). Yellowish solid (41 mg, 67%). 1HNMR(600MHz,DMSO-d6):δ11.09(br s,1H),7.83(d,J=8.0Hz,1H),7.69(d,J=8.0Hz,1H),7.37(s,1H),7.27–7.28(m,3H),6.41–6.44(m,1H),6.24–6.25(m,1H),5.07–5.10(m, 1H),4.10–4.12(m,2H),2.98–3.07(m,6H),2.85–3.91(m,5H),2.59–2 .63(m,5H),2.01–2.04(m,3H),1.84–1.87(m,3H),1.27–1.29(m,3H); 13 C NMR (150MHz, DMSO-d6): δ173.3,170.6,168.1,167.4,155.4,155.3,148.8,134.5,127.6,125.5,123.4,118.2,11 8.1,108.4,105.8,97.9,55.4,53.7,52.6,49.2,47.3,46.6,44.5,33.4,31.4,28.9,22.6.HRMS(EI):calcd.for[C 31 H 39 N8O6](M+H) + ,619.2987;found,619.2957.

[0254] Embodiment 30

[0255] Compound 12d was prepared, and its structural formula is as follows:

[0256]

[0257] Referring to the method of step (2) in Example 1, compound 11 was reacted with compound 4d to obtain compound 12d, a total of 37 mg, with a yield of 61%, as a yellow solid powder.

[0258] 5-(3-(((2-(4-(3-amino-4-nitrophenyl)piperazin-1-yl)ethyl)amino)methyl)piperidin-1-yl)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione(12d). Yellowish solid (37 mg, 61%). 1HNMR(600MHz,DMSO-d6):δ11.11(br s,1H),7.82(d,J=8.0Hz,1H),7.62(d,J=8.0Hz,1H),7.28(s,2H),6.40–6.42(m,1H),4.03–4.09(m,3H),3.93–3.95(m,3H),2.77– 3.02(m,5H),2.51–2.62(m,10H),1.99–2.03(m,1H),1.84–1.92(m,2H),1.74–1.77(m,1H),1.52–1.55(m,1H),1.24–1.31(m,1H); 13 C NMR (150MHz, DMSO-d6): δ173.2,170.5,167.5,166.8,155.4,154.3,152.6,148.7,142.2,130.0,127.6,123.4,112.3,1 09.6,105.8,97.9,54.5,53.3,52.8,49.8,49.4,47.6,46.7,37.7,31.8,31.4,29.5,22.6,21.5.HRMS(EI):calcd.for[C 31 H 39 N8O6](M+H) + ,619.2987;found,619.2958.

[0259] Embodiment 31

[0260] Compound 12e was prepared, and its structural formula is as follows:

[0261]

[0262] Referring to the method of step (2) in Example 1, compound 11 was reacted with compound 4e to obtain compound 12e, a total of 36 mg, with a yield of 58%, as a yellow solid powder.

[0263] 5-(4-(2-((2-(4-(3-amino-4-nitrophenyl)piperazin-1-yl)ethyl)amino)ethyl)piperidin-1-yl)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione(12e). Yellowish solid (36 mg, 58%). 1HNMR(600MHz,DMSO-d6):δ11.10(br s,1H),7.82(d,J=8.0Hz,1H),7.63(d,J=8.0Hz,1H),7.27(s,2H),6.40–6.42(m,1H),4.04–4.08(m,3H),3.92–3.96(m,3H),2.78 –3.02(m,7H),2.54–2.62(m,8H),1.99–2.06(m,1H),1.85–1.92(m,2H),1.73–1.78(m,1H),1.54–1.55(m,1H),1.23–1.33(m,1H); 13 C NMR (150MHz, DMSO-d6): δ173.1,170.4,167.6,167.0,155.8,154.9,153.0,148.8,142.3,130.1,128.1,123.6,112.5,1 09.7,106.0,98.0,54.6,53.4,52.9,49.4,49.1,47.8,46.9,38.1,32.0,31.8,29.5,22.8,21.9.HRMS(EI):calcd.for[C 32 H 41 N8O6](M+H) + ,633.3144;found,633.3150.

[0264] Embodiment 32

[0265] Compound 12f was prepared, and its structural formula is as follows:

[0266]

[0267] Referring to the method of step (2) in Example 1, compound 11 was reacted with compound 4f to obtain compound 12f, a total of 32 mg, with a yield of 49%, as a yellow solid powder.

[0268] 5-(4-(3-((2-(4-(3-amino-4-nitrophenyl)piperazin-1-yl)ethyl)amino)propyl)

[0269] piperidin-1-yl)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione(12f).Yellowish solid(32mg, 49%). 1HNMR(600MHz,DMSO-d6):δ11.08(br s,1H),7.83(d,J=8.0Hz,1H),7.67(d,J=8.0Hz,1H),7.33(s,1H),7.24–7.28(m,3H),6.42(d,J=8.0Hz,1H),6 .24(s,1H),5.06–5.09(m,1H),4.07–4.09(m,5H),2.90–2.99(m,3H),1.57–2.04(m,13H),1.18–1.30(m,10H); 13 C NMR (150MHz, DMSO-d6): δ173.3,170.6,168.1,167.4,155.4,148.8,134.5,127.6,125.5,123.4,118.1,117.8,108. 2,105.9,97.9,52.5,49.2,47.9,47.6,46.6,43.9,35.1,33.1,31.5,31.3,29.0,23.2,22.6.HRMS(EI):calcd.for[C 33 H 43 N8O6](M+H) + ,647.3300;found,647.3260.

[0270] Embodiment 33

[0271] Compound 12g was prepared, and its structural formula is as follows:

[0272]

[0273] Referring to the method of step (2) in Example 1, compound 11 was reacted with compound 4g to obtain compound 12g, a total of 33 mg, with a yield of 53%, and a yellow solid powder.

[0274] 5-(6-(((2-(4-(3-amino-4-nitrophenyl)piperazin-1-yl)ethyl)amino)methyl)-3-azabicyclo[3.1.0]hexan-3-yl)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (12g). Yellowish solid (33mg, 53%). 1HNMR(600MHz,DMSO-d6):δ11.08(br s,1H),7.82(d,J=8.0Hz,1H),7.65(d,J=8.0Hz,1H),7.27(s,2H),6.95(s,1H),6.8 5–6.86(m,1H),6.40–6.42(m,1H),6.23–6.24(m,1H),5.04–5.08(m,1H),3.68(d,J =6.0Hz,2H),3.41–3.52(m,6H),2.95–3.00(m,2H),2.82–2.91(m,3H),2.53–2.61( m,7H),2.00–2.03(m,1H),1.85–1.90(m,2H),1.24–1.25(m,1H),0.92–0.94(m,1H); 13 C NMR (150MHz, DMSO-d6): δ173.2,170.6,168.1,167.6,155.4,152.8,148.8,134.3,127.6,125.4,123.4,116.9,11 6.5,106.6,105.8,97.9,72.7,60.7,52.6,50.7,49.6,49.1,46.6,31.4,22.7,22.4,21.9.HRMS(EI):calcd.for[C 31 H 37 N8O6](M+H) + ,617.2831;found,617.2840.

[0275] Embodiment 34

[0276] Compound 13a was prepared, and its structural formula is as follows:

[0277]

[0278] Referring to the method of step (2) in Example 14, compound 11 was reacted with compound 9a to obtain compound 13a, a total of 44 mg, with a yield of 72%, as a yellow solid powder.

[0279] 5-(3-(((2-(4-(3-amino-4-nitrophenyl)piperazin-1-yl)ethyl)amino)methyl)-azetidin-1-yl)-2-(2,6-dioxopiperidin-3-yl)-6-fluoroisoindoline-1,3-dione(13a). Yellowish solid (44 mg, 72%).1 HNMR(600MHz,DMSO-d6):δ11.09(br s,1H),7.82(d,J=8.0Hz,1H),7.61(d,J=8.0H,1H),7.27(s,2H),6.90–6.92(m,1H),6.39–6.41(m,1H),6.22(s,1H),5.05–5.09(m,1H),4 .26(t,J=6.0Hz,2H),3.89–3.91(m,2H),3.35–3.50(m,3H),2.87–2.93(m,4H),2.78–2.86(m,2H),2.47–2.61(m,9H),2.00–2.04(m,1H); 13 CNMR (150MHz, DMSO-d6): δ173.2, 170.4, 167.3, 166.8, 155.4 (d, J = 210.4Hz), 154.8, 153.2, 144.6, 129.8, 127.6, 123.4, 111. 8(d,J=7.6Hz),108.3,105.8,99.9,97.8,72.7,60.7,57.6,55.4,52.8,49.4,46.7,31.4,29.8,22.6.HRMS(EI):calcd.for[C 29 H 34 FN8O6](M+H) + ,609.2580;found,609.2590.

[0280] Embodiment 35

[0281] Compound 13b was prepared, and its structural formula is as follows:

[0282]

[0283] Referring to the method of step (2) in Example 14, compound 11 was reacted with compound 9b to obtain compound 13b, a total of 43 mg, with a yield of 69%, as a yellow solid powder.

[0284] 5-(3-(((2-(4-(3-amino-4-nitrophenyl)piperazin-1-yl)ethyl)amino)methyl)

[0285] pyrrolidine-1-yl)-2-(2,6-dioxopiperidin-3-yl)-6-fluoroisoindoline-1,3-dione(13b). Yellowish solid (43 mg, 69%).1 HNMR(600MHz,DMSO-d6):δ11.10(br s,1H),7.81–7.84(d,J=8.0Hz,1H),7.61–7.63(d,J=8.0Hz,1H),7.26( s,2H),7.05–7.07(m,1H),6.40–6.42(m,1H),6.23(s,1H),5.06–5.09( m,1H),3.48–3.74(m,10H),2.81–2.93(m,4H),2.51–2.61(m,6H),2.11 –2.14(m,1H),2.01–2.04(m,1H),1.74–1.76(m,1H),1.24–1.26(m,1H); 13 C NMR (150MHz, DMSO-d6): δ173.2, 170.5, 167.5, 166.8, 155.4 (d, J = 210.3Hz), 154.3, 152.6, 148.7, 142.2, 130.1, 127.6, 123.4, 1 12.3(d,J=7.6Hz),109.6,105.8,97.9,54.4,52.8,49.8,49.4,46.7,31.7,31.4,29.5,29.4,22.6,21.6.HRMS(EI):calcd.for[C 30 H 36 FN8O6](M+H) + ,623.2736;found,623.2740.

[0286] Embodiment 36

[0287] Compound 13c was prepared, and its structural formula is as follows:

[0288]

[0289] Referring to the method of step (2) in Example 14, compound 11 was reacted with compound 9c to obtain compound 13c, a total of 40 mg, with a yield of 63%, as a yellow solid powder.

[0290] 5-(3-(((2-(4-(3-amino-4-nitrophenyl)piperazin-1-yl)ethyl)amino)methyl)piperidin-1-yl)-2-(2,6-dioxopiperidin-3-yl)-6-fluoroisoindoline-1,3-dione(13c). Yellowish solid (40 mg, 63%). 1HNMR(600MHz,DMSO-d6):δ11.12(br s,1H),7.81(d,J=8.0Hz,1H),7.71–7.73(m,1H),7.47(d,J=8.0Hz,1H),7.26(s,2H),6.38(d,J=8.0Hz,1H),6.20(s,1H),5.09–5.12(m,1 H),3.51–3.65(m,8H),2.70–2.96(m,7H),2.51–2.62(m,4H),1.98–2.05(m,2H),1.78–1.86(m,2H),1.63–1.65(m,1H),1.18–1.26(m,1H); 13 CNMR (150MHz, DMSO-d6): δ173.2,170.4,167.2,166.6,158.6,156.9,155.4(d,J=210.2Hz),146.4,129.2,127.6,123.6,1 14.4,112.5(d,J=7.6Hz),105.8,97.9,54.2,52.7,51.1,49.5,46.7,31.4,28.2,24.6,22.5,21.2.HRMS(EI):calcd.for[C 31 H 38 FN8O6](M+H) + ,637.2893;found,637.2874.

[0291] Embodiment 37

[0292] Compound 13d was prepared, and its structural formula is as follows:

[0293]

[0294] Referring to the method of step (2) in Example 14, compound 11 was reacted with compound 9d to obtain compound 13d, a total of 37 mg, with a yield of 58%, as a yellow solid powder.

[0295] 5-(3-(((2-(4-(3-amino-4-nitrophenyl)piperazin-1-yl)ethyl)amino)methyl)piperidin-1-yl)-2-(2,6-dioxopiperidin-3-yl)-6-fluoroisoindoline-1,3-dione(13d). Yellowish solid (37 mg, 58%). 1HNMR(600MHz,DMSO-d6):δ11.11(br s,1H),7.81(d,J=8.0Hz,1H),7.72–7.74(m,1H),7.46(d,J=8.0Hz,1H),7.26(s,2H),6.40(d,J=8.0Hz,1H),6.18(s,1H),5.09–5.12(m,1 H),3.50–3.59(m,8H),2.69–2.90(m,7H),2.50–2.64(m,4H),1.98–2.06(m,2H),1.80–1.88(m,2H),1.64–1.67(m,1H),1.20–1.27(m,1H); 13 CNMR (150MHz, DMSO-d6): δ173.5,170.6,167.0,166.9,158.8,157.0,155.6(d,J=210.1Hz),146.5,130.0,127.7,123.8,1 15.0,112.6(d,J=7.6Hz),106.0,98.0,54.3,52.8,51.2,49.4,46.6,31.6,28.4,24.5,22.6,21.4.HRMS(EI):calcd.for[C 31 H 38 FN8O6](M+H) + ,637.2893;found,637.2874.

[0296] Embodiment 38

[0297] Compound 13e was prepared, and its structural formula is as follows:

[0298]

[0299] Referring to the method of step (2) in Example 14, compound 11 was reacted with compound 9e to obtain compound 13e, a total of 44 mg, with a yield of 73%, as a yellow solid powder.

[0300] 5-(4-(2-((2-(4-(3-amino-4-nitrophenyl)piperazin-1-yl)ethyl)amino)ethyl)-piperidin-1-yl)-2-(2,6-dioxopiperidin-3-yl)-6-fluoroisoindoline-1,3-dione(13e). Yellowish solid (44 mg, 73%). 1HNMR(600MHz,DMSO-d6):δ11.10(br s,1H),7.81(d,J=8.0Hz,1H),7.72(d,J=8.0Hz,1H),7.44(d,J=8.0Hz,1H),7.26(s ,2H),6.42–6.44(m,1H),6.26(s,1H),5.10–5.14(m,1H),3.62–3.64(m,3H),3.08– 3.10(m,2H),2.88–2.94(m,6H),2.62–2.64(m,3H),2.54–2.57(m,4H),2.04–2.07( m,2H),1.80–1.83(m,2H),1.68–1.71(m,2H),1.46–1.49(m,2H),1.26–1.36(m,4H); 13 C NMR (150MHz, DMSO-d6): δ173.4, 170.4, 167.0, 166.8, 157.8 (d, J = 210.4Hz), 155.6, 148.8, 146.4, 146.2, 129.2, 128.0, 123.4, 114. 3,112.4(d,J=7.6Hz),106.0,98.0,53.6,52.6,50.4,49.5,47.3,46.6,44.0,34.8,33.0,31.9,31.2,22.8.HRMS(EI):calcd.for[C 32 H 40 FN8O6](M+H) + ,651.3049;found,651.3050.

[0301] Embodiment 39

[0302] Compound 13f was prepared, and its structural formula is as follows:

[0303]

[0304] Referring to the method of step (2) in Example 14, compound 11 was reacted with compound 9f to obtain compound 13f, a total of 32 mg, with a yield of 48%, as a yellow solid powder.

[0305] 5-(4-(3-((2-(4-(3-amino-4-nitrophenyl)piperazin-1-yl)ethyl)amino)propyl)

[0306] piperidin-1-yl)-2-(2,6-dioxopiperidin-3-yl)-6-fluoroisoindoline-1,3-dione(13f). Yellowish solid (32 mg, 48%). 1 HNMR(600MHz,DMSO-d6):δ11.12(br s,1H),7.82(d,J=8.0Hz,1H),7.72(d,J=8.0Hz,1H),7.46(d,J=8.0Hz,1H),7.28(s ,2H),6.42–6.44(m,1H),6.24(s,1H),5.10–5.13(m,1H),3.62–3.64(m,3H),3.08– 3.10(m,2H),2.87–2.95(m,6H),2.61–2.63(m,3H),2.54–2.57(m,4H),2.04–2.07( m,2H),1.79–1.82(m,2H),1.67–1.71(m,2H),1.47–1.50(m,2H),1.25–1.35(m,6H); 13 C NMR (150MHz, DMSO-d6): δ173.2,170.4,167.2,166.7,157.7(d,J=210.2Hz),155.4,148.8,146.3,146.2,129.2,127.6,123.4,114.2, 112.4(d,J=7.6Hz),105.9,98.0,53.6,52.5,50.5,49.5,47.5,46.6,43.9,34.8,33.1,31.9,31.4,31.1,22.6.HRMS(EI):calcd.for[C 33 H 42 FN8O6](M+H) + ,665.3206;found,665.3172.

[0307] Embodiment 40

[0308] Compound 13g was prepared, and its structural formula is as follows:

[0309]

[0310] Referring to the method of step (2) in Example 14, compound 11 was reacted with compound 9g to obtain compound 13g, a total of 33 mg, with a yield of 52%, and a yellow solid powder.

[0311] 5-(6-(((2-(4-(3-amino-4-nitrophenyl)piperazin-1-yl)ethyl)amino)methyl)-3-azabicyclo[3.1.0]hexan-3-yl)-2-(2,6-dioxopiperidin-3-yl)-6-fluoroisoindoline-1,3-dione(13g).Yellowish solid(33mg,52%). 1 HNMR(600MHz,DMSO-d6):δ11.10(br s,1H),7.82(d,J=8.0Hz,1H),7.63(d,J=8.0Hz,1H),7.27(s,2H),7.11(d,J=8.0Hz,1H),6.40–6.42(m,1H),6.23(s,1H),5.06–5.09(m,1H), 4.58(s,1H),3.83–3.85(m,2H),3.58–3.60(m,2H),3.41–3.51(m,3H), 2.82–3.00(m,3H),2.00–2.04(m,1H),1.80(s,1H),1.24–1.34(m,1H); 13 C NMR (150MHz, DMSO-d6): δ173.2, 170.5, 167.4, 166.8, 155.4 (d, J = 210.4Hz), 152.9, 148.8, 142.3, 129.8, 127.6, 123.4, 112.4, 1 11.1(d,J=7.6Hz),105.8,99.9,97.6,79.2,72.7,67.2,60.7,52.6,52.4,49.4,46.6,31.4,22.6,22.1.HRMS(EI):calcd.for[C 31 H 36 FN8O6](M+H) + ,635.2736;found,635.2762.

[0312] Experiment to explore the degradation efficiency of compounds on SIRT6 protein

[0313] SK-HEP-1 cells were seeded in a 96-well black plate, with 6 × 10 cells per well. 4 / 100μL, after 12h, add the corresponding dose of degradation agent or DMSO (control well). After incubation in the incubator for 36h, add 75μL of 8% formaldehyde TBS solution to each well and fix it at room temperature for 20min. Remove the solution in the well, wash twice with 200μL / well TBST, add 50μL / well 0.1% Triton X PBS solution, and let it stand for 15min. Remove the solution in the 96-well plate, wash twice with 150μL / well TBST. Then add 100μL / well 1% H2O2 / TBS solution and incubate at room temperature for 20min. Remove the solution and wash 3 times with an appropriate amount of TBST. Add 50μL of blocking solution to each well and incubate overnight at 4℃. Remove the blocking solution, add 100μL of SIRT6 antibody blocking solution diluted 1:2000 to each well, and add DMSO to the control group, and incubate at room temperature for 2h. Recover the SIRT6 primary antibody, wash twice with an appropriate amount of TBST, add 150 μL of HRP-labeled rabbit antibody to each well, and incubate at room temperature for 1 hour. Remove the secondary antibody and wash 3 times with TBST. Add 100 μL of pre-prepared TMB substrate solution to each well and incubate for 20 minutes at room temperature away from light. Add 10 μL of 1N HCl stop solution to each well and shake for 5 minutes. Test and record the absorbance values ​​at 450 and 570 nm on a densitometer and calculate the relative content of SIRT6 protein. The results are shown in Table 1.

[0314] Table 1 Degradation efficiency of SIRT6 protein by each compound at high and low concentrations

[0315]

[0316]

[0317] Western Blot SIRT6 protein degradation experiment

[0318] After SK-HEP-1 or Huh-7 cells were treated with the above compounds at different concentrations or time points, RIPA was added for lysis in an ice bath for 30 minutes, and then a protease degrader was added. The protein concentration was quantitatively tested using a BCA kit. An equal amount of protein was taken and electrophoresed with 10-12% mass fraction polyacrylamide. The protein bands were transferred to a PVDF membrane and blocked with 5% skim milk for 1 hour. The target bands were incubated with the corresponding primary antibody at 4°C for 12 hours, washed with TBST, and then incubated with a secondary antibody labeled with caprylic peroxide at room temperature for 1 hour. After washing with TBST, the immunofluorescence substrate was added and chemical fluorescence imaging was performed quickly. The test results are as follows. Figure 1 , 2 , as shown in Figure 3.

[0319] according to Figure 1 and 2The test results showed that compounds 6b, 6c, 6e, 6h, 10b, 10c, 10f, 10l and 10m can significantly and selectively degrade SIRT6 protein in tumor cells in a concentration-dependent manner, and compounds 10c and 10f can degrade GSPT1 protein in liver cancer cells in a concentration-dependent manner. Figure 3 The test results showed that compounds 6e, 6f, 10e, 10j and 10m were able to degrade SIRT6 protein in liver cancer cells Huh-7.

[0320] Animal model experiments

[0321] Four-week-old BALB / c nude mice were purchased and raised for another week before being inoculated with SK-HEP-1 (1×10 7 After waiting for about 10 days, the size of the tumor was measured. When the tumor volume was 150-200mm 3 The mice were randomly divided into four groups (blank group, PROTAC group (10 mg / Kg), Sorafenib group (25 mg / Kg) and combination group (Sorafenib (25 mg / Kg) + PROTAC (10 mg / Kg)), with 4 mice in each group. The drugs were administered every other day for 28 consecutive days. The mice were carefully observed and weighed every day. Finally, after the mice were anesthetized and euthanized, the tumors were removed, weighed, and the tumor-related indexes were measured.

[0322] In this animal model experiment, the PROTAC group consisted of compound 10c.

[0323] Figure 4 The experimental results showed that the PROTAC group can inhibit tumor proliferation, and the combination with Sorafenib can significantly inhibit tumor proliferation.

[0324] It can be understood that compound 10c and the compounds represented by the general formula (1) provided by the present invention, such as compounds 6a-6m, 10a-10m, 12a-12g and 13a-13g, have the same protein ligand and ligase ligand. Those skilled in the art can reasonably expect that the compounds provided by the present invention, such as 6a-6m, 10a-10m, 12a-12g and 13a-13g, also have the effect of inhibiting tumor proliferation like compound 10c, and can significantly inhibit tumor proliferation when used in combination with existing anticancer drugs.

[0325] In the above embodiments, the description of each embodiment has its own emphasis. For parts that are not described in detail in a certain embodiment, reference can be made to the relevant descriptions of other embodiments.

[0326] The above is a specific embodiment of the present invention, but the protection scope of the present invention is not limited thereto. Any technician familiar with the technical field can easily think of various equivalent modifications or replacements within the technical scope disclosed by the present invention, and these modifications or replacements should be included in the protection scope of the present invention. Therefore, the protection scope of the present invention shall be based on the protection scope of the claims.

Claims

1. A degrader targeting SIRT6 and / or GSPT1, It is characterized in that It includes a compound having the structure of general formula (1) or a pharmaceutically acceptable salt thereof; In the formula, X is selected from hydrogen or fluorine; M is selected from fluorine, halogen, methyl, methoxy, phenyl, benzyl, nitro, nitrile, 2 / 3-thienyl, 2 / 3-pyridyl, 2 / 3-furyl, N-pyrazolyl, N-piperidine, aniline; The value of y is 0 or 1; the value of z is 0 or 1; The linker is at least one of an aromatic chain, an aliphatic heterocyclic structure chain, and an aromatic heterocyclic structure chain containing at least one tertiary amine group.

2. The degradation agent according to claim 1, It is characterized in that The structure of the linker is selected from any one of the structural formulas (a) to (l): In the structural formulas (a)-(l), the value of m is 0-10, and the value of n is 1-8.

3. The degradation agent according to claim 2, It is characterized in that The compound has a structure shown in any of the following:

4. The degradation agent according to claim 3, It is characterized in that The preparation methods of the compounds 6a-6m and 10a-10m are as follows: Compound 1 or compound 7 is subjected to a Hofmann alkylation reaction with a linker having an amine group at one end and an alcohol group at the other end to generate an intermediate compound containing an alcohol group; Oxidizing the alcohol group of the intermediate compound and reacting with compound 5 to obtain any one of compounds 6a-6m and 10a-10m; The structural formula of the compound 1 is as follows: The structural formula of the compound 7 is as follows: The structural formula of the compound 5 is as follows:

5. The degradation agent according to claim 3, It is characterized in that The preparation methods of the compounds 12a-12g and 13a-13g are as follows: Compound 1 or compound 7 is subjected to a Hofmann alkylation reaction with a linker having an amine group at one end and an alcohol group at the other end to generate an intermediate compound containing an alcohol group; Oxidizing the alcohol group of the intermediate compound and reacting it with compound 11 to obtain any one of compounds 12a-12g and 13a-13g; The structural formula of the compound 1 is as follows: The structural formula of the compound 7 is as follows: The structural formula of the compound 11 is as follows:

6. The degradation agent according to claim 5, It is characterized in that The compound 11 is obtained by reacting the compound 5 with a compound containing an amine protecting group; The structural formula of the compound 5 is as follows: The structural formula of the compound containing amine protecting group is as follows:

7. The degradation agent according to claim 4 or 5, It is characterized in that The amine group is a secondary amine group.

8. The degradation agent according to claim 4 or 5, It is characterized in that The alcohol group of the intermediate compound is oxidized using Dess-Martin periodinane.

9. A pharmaceutical composition, It is characterized in that The pharmaceutical composition comprises the degrader targeting SIRT6 and / or GSPT1 according to any one of claims 1 to 8.

10. Use of the SIRT6 and / or GSPT1 targeting degrader according to any one of claims 1 to 8 in the preparation of a regulator or anti-tumor drug targeting SIRT6 and / or GSPT1 protein.